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The development of medical device software is strictly regulated by competent 
authorities. In addition to producing significant medical benefits, the medical device 
software can be a potential source of serious safety hazard to patients or healthcare 
professionals. The International Standard ISO 14971 was created to minimize the risks 
related to treatment of patients with the medical devices.  
Although agile software development has become a widely used method for 
developing software products, medical device manufacturers and regulators have been 
uncertain whether these practices are appropriate for the regulated environment. The 
purpose of this thesis is to research similarities and differences between ISO 14971 risk 
management process and agile principles. Furthermore, the aim is also to provide 
guidance and produce practical ideas for the implementation of the risk management 
process that meets the regulatory requirements and follows agile values and principles. 
The risk management standard ISO 14971 was thoroughly analyzed in order to find 
all process requirements. Similarly, the agile practices were studied through the Agile 
Manifesto and other essential resources of the field. The synthesis of the two concepts 
was produced based on the information gathered.  
The ideas produced in the research are presented as an example development process 
model which can be used as a reference implementation. The relatively high abstraction 
level of the model secures the generalizability of the research. 
When designing the risk management process implementation, it is essential to 
thoroughly understand the goals and principles of the regulatory framework. By 
following the guidance and instructions provided in this thesis, medical device software 
manufacturers should be able to create the applicable risk management process and to 
claim conformity to ISO 19471. 
 
Key words and terms: Medical device software development, Software development, 
Quality management systems, Risk management, Agile methods. 
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1. Introduction 
Manufacturing of medical devices is strictly controlled by national authorities. The safety 
of people and healthcare are among the main concerns of governments. In the EU region, 
there is a regulatory framework run by the European Commission and it consists of three 
core directives. The European Commission has ongoing international cooperation 
between the most important interest parties and is also participating to a multilateral 
framework, the International Medical Device Regulators' Forum (IMDRF) [European 
Commission, 2016]. In Finland, medical device manufacturing is controlled by the 
National Supervisory Authority for Welfare and Health Valvira [Valvira, 2009]. 
One of the core directives is the Council Directive 93/42/EEC on Medical Devices 
(MDD) [1993]. MDD is the most crucial directive that regulates the medical device 
manufacture process in the EU area (excluding only active implantable and In Vitro 
devices that are being addressed in specific directives) [European Commission, 1990, 
1998]. A company marketing their medical devices in the EU must prove compliance 
with the MDD [European Commission, 1993] and in the US market regulations of The 
Food and Drugs Administration (FDA) must be met. One of the most essential ways to 
meet these regulations is to implement the requirements of the Quality Management 
System (QMS) as defined in ISO 13485 standard. It is a QMS standard for medical 
devices and it is harmonized with MDD in the EU and it is also accepted by the FDA 
[2012]. It also defines the risk management process that is required within the medical 
device manufacturing process by making normative reference to ISO 14971. 
1.1. Risk management regulation 
The International Standard ISO 14971 was prepared with a mandate by the European 
Commission. It provides a means of conforming the risk management requirements of 
MDD [ISO, 2012]. It is a de facto standard and commonly recognized as one of the best 
processes to implement the risk management process for medical devices, taking care of 
the whole lifecycle of the medical device in question [Catelani et al., 2011]. Faris [2006] 
estimated that over half of the medical devices on sale in the US market contained some 
form of software and it is safe to assume that the ratio has not decreased since, on the 
contrary. However, MDD does not differentiate between the physical medical device 
(with or without software) or medical device software that is used as a medical device 
and exists without any specific physical device - the software is considered to be a 
medical device as such [European Commission, 1993]. Therefore, the same medical 
device standards and regulations must be used when manufacturing software for use in 
the medical domain. 
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1.2. Agile development success 
At the same time, agile software development has grown increasingly popular over the 
last decade [VersionOne, 2016]. Agile practices have pervaded from small pioneering 
companies to the whole field of software development organizations. The growth has 
definitely been rapid, considering that the agile movement is practically only 15 years 
old. However, the roots of the movement are considerably older [Poppendieck & 
Poppendieck, 2003].  
The importance and impact of agile philosophy cannot be denied. The number of 
software development organizations using agile practices continues to increase every 
year and the phenomenon is growing globally. According to VersionOne survey [2016], 
besides North America and Europe, agile is getting more practitioners also in Asia, South 
America, Oceania and Africa.  
The popularity of agile is based on the belief that adopting agile practices helps 
organizations to succeed. The promise of agile is accelerated development, increased 
product quality, customer satisfaction and ability to respond to change. Furthermore, the 
increased development process visibility can be seen as an advantage. Besides gaining 
more popularity inside the software development domain, agile has become a largely 
used methodology also in other complex development environments. This evolvement is 
natural from the historical viewpoint since agile has taken strong influence from lean 
manufacturing industry.  
1.3. Barriers to agile adoption in regulated environment 
Although adopting agile practices is generally seen as a desirable goal, there can be 
certain obstacles to overcome. It is common that organizational culture prevents 
development teams from being truly agile when top management is not giving consistent 
support for new ways to work. Besides the company culture, existing development 
framework and lack of experience in agile practices can become a complication 
[VersionOne, 2016]. 
 Highsmith [2004] states that every development organization, team and project has 
some compliances to meet. These compliances can be seen as obstacles to agile adoption, 
although the restrictive impact of certain compliance depends highly on the type and the 
complexity of the obstacle in question. It is evident that the medical device development 
regulatory framework produces a great deal of complicated compliances.  
McHugh et al. [2014] studied the perceived barriers to following agile practices 
when developing medical device software. The questionnaire-based survey part of the 
study revealed that exactly regulatory control and traceability issues were seen as barriers 
for agile adoption by participant organizations. However, McHugh et al. [2014] argues 
that, based on the study, these barriers are only superficial and no actual external barriers 
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to adopting agile practices exists. Nevertheless, the survey acts as an evidence that 
guidance for agile adoption in medical device software domain is needed.  
AAMI TIR45 Technical Information Report [2012] provides practical guidance for 
agile adoption for medical device software development. The guidance given in the 
document is based on the information from the actual agile implementations in the 
medical device software domain. While AAMI TIR45 is an important and highly 
recommended reference for agile adoption, it is mainly focused on software lifecycle 
processes requirements of IEC 62304, therefore the risk management requirements of 
ISO 14971 are not addressed with great level of detail. Conversely, previous studies of 
ISO 14971 risk management, for example Schmuland [2005] and Flood et al. [2015], do 
not address aspects of agile development.  
The risk management is a key activity for organizations developing medical device 
software. However, it is a difficult and time-consuming task to define a suitable process 
to meet the regulatory requirements [Flood et al, 2015]. In conclusion, practical guidance 
for risk management process implementation and agile adoption is needed.   
1.4. Research objectives, methods and outcomes 
The aim of this research is to produce practical ideas how to implement the requirements 
of ISO 14971 while consistently following agile principles. The agile principles and the 
risk management process are examined. The research aims to discover the principles of 
integration between these two concepts and should also gain knowledge about the 
suitable integration. 
The research questions are: 
1) How to implement the requirements of the ISO 14971 in compliance with the 
agile principles? 
2) Are there any non-compliances between the ISO 14971 process model and 
agile principles? 
3) If there are non-compliances, how to solve them? Should the agile software 
development framework be tailored in some way? 
 
The research is a case study of the risk management process standard ISO 14971. The 
standard is analyzed thoroughly and all the requirements are gathered. The risk 
management process is sectioned to appropriate phases and inside the phases to more 
detailed steps. All the requirements of the standard should be satisfied by following these 
defined steps. 
Simultaneously, the agile development principles are examined from the general 
point of view. Agile software development is a general topic and considerable amount of 
quality literature can be found. Therefore, this research concentrates on seminal or 
otherwise essential works of the field. It is important to limit the irrelevant details of some 
specific agile software development method. Instead, the focus is on the general 
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principles and guidelines of the agile philosophy. This approach secures the 
generalizability of the research. On the other hand, it is essential to notice that practical 
quality management system and risk management process implementations can only be 
made on a case by case basis [Schmuland, 2005]. 
The rest of this thesis is arranged as follows. Chapter 2 presents the background of 
regulatory framework behind the risk management process of ISO 14971. Chapter 3 
analyzes the process requirements of ISO 14971 and addresses also the risk management 
requirements of IEC 62304. Chapter 4 defines the agile grounding and perspective of this 
study. Chapter 5 studies the similarities and differences between agile and regulatory 
perspectives and justifies the rationale behind agile methodology adaptation. Chapter 6 
presents the practical guidance and a reference development model for risk management 
process and agile development synthesis. Chapter 7 concludes the thesis.   
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2. Regulatory perspective 
The manufacturing of medical devices and medical device software inside EU region is 
strictly controlled by EU directives. The directive covering the medical device software 
is Council Directive 93/42/EEC on Medical Devices [MDD, 1993], although other 
directives may also apply, depending on the type of the software product. For example, 
The European Parliament and Council Directive 2011/24/EU controls the use of patient's 
personal data [European Commission, 2011]. As the directives require EU countries to 
achieve a certain result, they must be properly implemented in national legislation 
[European Union, 2016]. The main goal of the regulatory framework is to protect the 
health and safety of patients and medical device users by guarding public against unsafe 
medical products. 
It is obvious that it would be practical if the similar medical device regulations 
applied in all countries. This kind of harmonization work has been made first by the 
Global Harmonization Task Force (GHTF) and then by the International Medical Device 
Regulators Forum (IMDRF). The organizations like the International Organization for 
Standardization (ISO) and International Electrotechnical Commission (IEC) are 
producing international standards from which notable part is harmonized inside EU. 
These standards are called harmonized standards in EU region and recognized standards 
in USA and Canada. 
MDD provides only general requirements for the medical device manufacturing 
process while the details of the implementation are left to manufacturers to define [AAMI 
TIR45, 2012]. MDD does not demand manufacturers to use the harmonized standards, 
however strong justification must be provided if standards are not followed. In practice, 
the standards form a very useful tool to prove that the regulations of MDD have been 
implemented. The standards can also provide some ready-made solutions for 
implementation of MDD while allowing manufacturers to create their own practices to 
align with regulations.  
The harmonized standards that must be currently taken into consideration in the 
medical device software manufacture process are presented in Figure 1 and addressed 
with more detail later in this chapter. One of the most central theme in these standards is 
that the medical device software must be safe and effective. The standards also cover the 
post-production phase of the software with the concepts of post-market surveillance and 
incident reports. Overall, the regulatory requirements and standards provide a framework 
for medical device software development practices while leave a responsibility to tailor 
the details of the development process for the manufacturer. 
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Figure 1. Relationship of key medical device standards to IEC 62304 [IEC 62304, 
2006]. 
2.1. ISO 13485 
ISO 13485:2003, Medical devices – Quality management systems – Requirements for 
regulatory purposes is a widely acknowledged standard that defines requirements for the 
quality management system for the design and manufacture process of medical devices. 
ISO 13485 is heavily based on ISO 9001, which is maybe the most commonly known 
quality management system standard, but it is a stand-alone standard tailored for 
application to the medical device sector and its requirements are specific to medical 
device domain. ISO 13485 states that the adoption of the quality management system 
should be a strategic decision of an organization and the implementation is influenced by 
varying aspects [ISO, 2003]. It also adds an obligation for organization to establish a risk 
management system. 
It is worth to notice that some of the definitions provided in ISO 13485 can be 
superseded by local regulations. Furthermore, it excludes some of ISO 9001 requirements 
that are not suitable as regulatory requirements in the medical domain. For this reason, 
organizations implementing ISO 13485 must also conform to all the requirements of ISO 
9001 if they want to claim conformity to ISO 9001 [ISO, 2003]. ISO 9001 is not sufficient 
for manufacture process of medical devices, but it can be otherwise beneficial for 
example in competitive tendering. Broadly, the requirement level of ISO 13485 is more 
demanding than ISO 9001. 
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ISO 13485 defines general requirements for the quality management system. The 
principle of the standard is that everything must be documented and what is not 
documented does not exist [Ståhlberg, 2015]. Terms "if appropriate" and "where 
appropriate" are used in standard several times. When these terms are used in conjunction 
with a regulation, the regulation in question is deemed to be appropriate unless the 
organization can document a justification otherwise. If the regulation is specified to be 
"documented", it must also be implemented and maintained. 
Furthermore, quality manual and control of document and record requirements are 
interpreted. The purpose of these documents and records is to be able to demonstrate that 
predefined processes of the standard and the quality management system itself have been 
followed on all occasions. Traceability is one of the most central subjects in the quality 
management system. All the occurred nonconformities must be handled with corrective 
and preventive action process.  
ISO 13485 emphasizes management responsibility of the organization. Management 
commitment, responsibilities, authorities, quality policy and internal communication are 
regulated topics. The quality management system must have a top management 
representative who is responsible for the system and the system must be reviewed by the 
management at planned intervals. As a part of the quality management system, 
organization must be aware about the laws, regulations and requirements that apply to 
operation of the organization. The personnel whose work affects the quality of the end 
product must be competent and the competence must be evaluated. 
Other topics of the standard are external supplier purchasing process, production and 
service provision, identification of end product and control of possible monitoring and 
measuring devices. The production process of the medical device must be carefully 
planned and plan must be followed accordingly during the production phase. Also 
monitoring the quality of the quality management system itself must be done by gathering 
feedback from the appropriate feedback system and by performing internal audits. Design 
and development controls of the standard can be excluded from the quality management 
system if other effective regulatory requirements permit. 
One of the interesting differences between ISO 9001 and ISO 13485 is that the later 
has eliminated the commitment to continually improve the quality management system 
in favor for continually maintain the effectiveness of the system. ISO 13485 [2003, 
Annex B, 8.1] states that "the objective of medical device regulations is the maintenance 
of the effectiveness of the quality management system to consistently produce medical 
devices that are safe and effective, not the continual improvement of the quality 
management system". However, as noted previously, if the organization wishes to meet 
also the requirements of ISO 9001, it has to make a commitment to continuous 
improvement. The process model of ISO 9001 is presented in Figure 2.  
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Figure 2. Model of a process-based quality management system [ISO 9001:2008]. 
The practical guidelines for ISO 13485 implementation can be found from ISO/TR 
14969 technical report. 
2.2. IEC 62304 
IEC 62304:2006, Medical device software – Software lifecycle processes -standard 
defines the lifecycle requirements for medical device software. It consists of processes, 
activities and tasks that combine a common framework for software lifecycle processes. 
The general goal of the standard is to improve safety and effectiveness of medical device 
software by establishing a process that reveals what the software is intended to do and to 
demonstrate that the software fulfills those objectives without unacceptable risks [IEC, 
2006]. The most important matters of IEC 62304 are software development and software 
maintenance. 
According to IEC 62304 [2006], the basic assumption is that the medical device 
software is being developed and maintained within the quality and risk management 
systems. As the risk management system is well covered by the ISO 14971 standard, IEC 
62304 addresses the risk management process by only making normative reference to 
ISO 14971 and adding some minor software related additions. These additions are 
covered later in Chapter 3 where ISO 14971 is discussed with more detail.  
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IEC 62304 emphasizes the importance of the software maintenance process as many 
incidents in the field are related to maintenance or service of medical device systems. For 
this reason, the maintenance process is considered to be as important as the actual 
development process. According the Clause 5, the software development process 
includes following activities:  
1) software development planning, 
2) software requirements analysis, 
3) software architectural design, 
4) software detailed design, 
5) software unit implementation and verification, 
6) software integration and integration testing, 
7) software system testing, 
8) software release. 
The activities are further divided to more specific tasks. Similarly, Clause 6 contains the 
maintenance process with following activities:  
1) establish maintenance plan, 
2) problem and modification analysis, 
3) modification implementation. 
The maintenance activities are also divided to specific tasks. Besides these concepts,  the 
software configuration management and the software problem resolution processes are 
identified in IEC 62304. 
IEC 62304 clearly states that its scope includes both embedded software in physical 
medical devices and standalone software that itself is a medical device. However, the 
standard does not cover validation or final release of the device. One crucial concept in 
IEC 62304 is software safety classification since different standard clauses are applied to 
different device safety classes, thus allowing manufacturers to tailor their processes to 
match with the classification. 
The safety classes are assigned based on severity [IEC 62304]:  
1) Class A: No injury or damage to health is possible. 
2) Class B: Non-serious injury possible. 
3) Class C: Death or serious injury possible. 
It is worth to notice that the assigned software safety classification can be reduced by one 
class (that is, from C to B or from B to A) if appropriate hardware risk control measure 
is applied. The risk control process is covered in more detail in Chapter 3. 
2.3. IEC 62366-1 
The usability and safe use of medical devices has become increasingly important concern 
since the medical devices have become more complex and they are being used even by 
the patients themselves. IEC 62366-1:2015 Medical Devices – Part 1: Application of 
usability engineering to medical devices is a usability engineering process standard that 
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defines processes to analyze, specify, develop and to evaluate medical device usability. 
The general goals of the standard are to achieve reasonable usability to minimize use 
errors and use-associated risks and to protect the safety of the patient and the medical 
device operator [IEC, 2015]. 
The original purpose of IEC 62366 was to present a usability engineering process for 
physical medical devices. The standard, especially the revised version, can be used also 
with medical device software, although special consideration for software related matters 
is not offered besides few incoherent examples. 
The main intention of the standard is to optimize the usability of medical device as it 
relates to safety. Part 1 of the standard describes the usability engineering process, while 
part 2 provides guidance how to comply the first part of the standard. The scope of the 
standard includes normal use of the medical device, that is correct use and typical use 
errors. It can also be used to identify abnormal use related risks, but it cannot be used to 
assess or mitigate them. 
The scope and implementation details of the usability engineering process can be 
selected case by case. This allows the organization to tailor the process based on the type 
of the medical device in question. If the user interface is simple, or there otherwise exists 
little safety issues, the complexities of the usability process can be reduced. The standard 
presents some implementation methods for different tasks, but using the offered methods 
is not compulsory. The implementation suggestions are not overly detailed so there might 
be need to seek guidance from external literature sources. From this point of view, it is 
not enough just to follow the text from the standard - some additional usability 
engineering understanding is needed in order be able to select the applicable methods. 
It is appropriate to notice that IEC 62366-1 has strong relation to ISO 14971 risk 
management standard. For example, when manufacturer uses information for safety as a 
risk control measure, this information must be conducted following the usability 
engineering process (ISO 14971 and the concept of risk control measure is presented in 
the chapter 3). In practice, this information for safety, for example warning tag or 
operation manual, must be designed with the same iterative process that the user interface.  
The closer analysis of IEC 62366-1 is left outside the scope of this thesis. 
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3. Analysis of ISO 14971 
ISO 14971:2012, Medical devices – Application of risk management to medical devices 
is a worldwide recognized standard used for medical device risk management. It defines 
a framework and minimum boundaries for risk management activities. The most 
important goal of performing formal risk management process activities is the assessment 
of overall residual risk [Schmuland, 2005].  
ISO 14971 is needed when the manufacturer wants to claim conformity to IEC 62304 
since IEC 62304 makes a normative reference to ISO 14971 requiring its use [IEC, 2006]. 
The compliance to ISO 14971 is needed to sell medical devices in EU region and Canada 
and it is recognized by the FDA as a way to meet the intention of the regulatory 
requirements.  
3.1. Key terms of ISO 14971 
ISO 14971 uses certain risk management related key terms that are important in order to 
understand the meaning of the standard. First, harm means physical injury or damage to 
the health of people, or damage to property or the environment. It is worth to notice that 
this definition has a major effect regarding the scope of the risk management process of 
ISO 14971 as it limits out all the development project related issues. Second, hazard is a 
potential source of harm and there can be several different causes for the hazards [IEC, 
2009].  Third, a hazardous situation is a circumstance where hazard occurs. Therefore, as 
defined in ISO 14971, a hazard cannot directly result in harm – a hazardous situation is 
needed before harm can occur. IEC/TR 80002-1 [2009] provides a clarifying example:  
“Unlike heat, electrical energy or suspended masses, software is not itself a 
HAZARD (a potential source of HARM); contact with software cannot 
cause injury. However, software may cause a person to be exposed to a 
HAZARD, in other words it may contribute to a HAZARDOUS 
SITUATION. Software failures (of any kind) often facilitate the 
transformation of a HAZARD into a HAZARDOUS SITUATION.” 
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Figure 3. Pictorial representation of the relationship of hazard, sequence of events, 
hazardous situation and harm [ISO 14971, 2012]. 
Furthermore, risk is defined as combination of probability of occurrence of harm and the 
severity of that harm. Consequently, the concept of specific risk does not exist before risk 
estimation is given - the hazard transforms to risk during the risk estimation phase. The 
difference is little more than a semantic in spoken language, but it is useful to be able to 
differentiate the two concepts in the risk management context. The pictorial presentation 
of the key terms is presented in Figure 3. 
3.2. Risk management personnel and responsibilities 
ISO 14971 states that the personnel performing risk management tasks must have 
required knowledge of risk management and qualification records to provide objective 
evidence must be maintained. The personnel must be trained to ensure full understanding 
of risk management process requirements. Furthermore, domain knowledge, both clinical 
and software development, is needed to be able to identify and estimate potential hazard 
scenarios. According to ISO 14971, the understanding is needed from: 
1) How the device is constructed. 
2) How the device works. 
3) How the device is produced. 
4) How the device is actually used. 
5) How to apply the risk management process. 
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ISO 14971 recommends the use of multidisciplinary team in practical risk management 
related work. For confidentiality reasons, the qualification records can be maintained 
outside of the quality management system. 
The top management commitment is essential for the effectiveness of the risk 
management process because: 
1) Risk management activities are less effective if resources are inadequate. 
2) Risk management is a specialized discipline and requires training. 
3) Top management is required to establish a risk management policy that 
defines how risk acceptance is determined. 
4) Risk management is an evolving process and should be periodically 
evaluated. 
3.3. Risk management plan and documentation 
ISO 14971 states that the risk management activities for a certain product development 
must be planned and these plans are presented in the risk management plan document. 
The risk management plan must include: 
1) The scope of the risk management process. 
2) Assignment of responsibilities and authorities. 
3) Requirements of reviews. 
4) Risk acceptability criteria (based on the company risk management policy), 
including criteria for risks when the probability cannot be estimated. 
5) Verification activities. 
6) Production and post-production activities. 
The risk management plan should prove that the organization uses an organized approach 
to risk management and can act as a checklist to ensure that all essential issues have been 
addressed. The plan does not need to be created at once, it can evolve over time. In 
addition, the risk management plan should also 1) describe the functionality of the 
medical device implemented in software, 2) state that the software will be developed 
according to standards and 3) reference to development aspects unique to software risk 
management [IEC, 2009]. The risk management plan does not need to be a specific file 
with a specific title, the actual document can be embedded into the quality management 
system.  
Every risk management process requirement that needs to be documented will be 
documented in the risk management file. The risk management file can be in any form or 
type of medium. It does not need to physically contain all the documents; references and 
pointers are sufficient. The term risk management file is used in standard to signify where 
all risk management related records and documents can be found. In practice, the risk 
management file is commonly embedded into the quality management system. Besides 
collecting evidence and records from other phases of the risk management process, the 
risk management file must provide traceability from each identified hazard to:  
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1) The risk analysis. 
2) The risk evaluation. 
3) The implementation and verification of the risk control measures. 
4) The assessment of the acceptability of any residual risk(s) [ISO, 2012]. 
Certain parts of the risk management file should be able to address software related 
changes and different release versions without compromising the traceability. 
Traceability is needed to demonstrate that the risk management process has been applied 
to all identified hazards and thus to prove the completeness of the risk management 
process.  
3.4. Risk management process lifecycles 
ISO 14971 defines the basic elements to be included to the risk management process. As 
can be seen in Figure 4, the process baseline can be divided to six specific lifecycle 
phases:  
1) Risk analysis. 
2) Risk evaluation. 
3) Risk control. 
4) Overall residual risk evaluation. 
5) Risk management report. 
6) Production and post-production information. 
3.5. Risk analysis 
Risk analysis is an activity to systematically use available information to identify hazards 
and estimate risks. In risk analysis phase, the analyzed medical device is described and 
identified, with the identification of persons and organization who performed risk 
analysis. Furthermore, the date and scope of the analysis must be recorded. Standard 
informs that if any previous risk analysis data or other relevant information is available 
for similar medical device, this information should be used as a starting point to save time 
and effort. However, some caution is obviously needed when evaluating the compatibility 
of the previous analysis and the current one. 
The intended use of the medical device is documented, as well as reasonably 
foreseeable incorrect use. When considering these issues, the focus should be on all those 
characteristics of the device that could affect to the safety. For example, it's not unusual 
that medical device is being used outside of normal intended circumstances - the 
manufacturer should be prepared for the potential hazards arising from these situations. 
Based on the previously collected list of safety related characteristics, all the 
predictable potential hazards should be identified. It is noticeable that the hazards should 
be considered in both routine and inadequate conditions. 
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Figure 4. A schematic representation of the Risk Management Process [ISO 14971, 
2012]. 
The final step of risk analysis is to identify hazardous situations and to estimate 
related risks. All the sequences of events that can lead to an identified hazard are 
hazardous situations which shall be documented and further analyzed. Every identified 
hazardous situation must be estimated with the help of available data. This information 
can be, for example, expert opinion, scientific technical data, field data from similar 
medical devices already in production use or usability tests. In estimation, the risk related 
to a hazardous situation is assessed with probability of occurrence and severity of harm 
(of realized hazard). The risk estimation is difficult task since the key factors of 
estimation vary between every hazardous situation. 
3.6. Risk evaluation 
Risk evaluation is a straightforward task: every identified and estimated risk is compared 
to acceptance criteria defined in the risk management plan. The decision whether risk 
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reduction is needed or not is solely based on the acceptance criteria. It is worth to notice 
that the standard does not specify any kind of concrete criteria, so the decision is left to 
the manufacturer. The justification to risk acceptance criteria must be given to a 
regulatory-approval body.  
3.7. Risk control 
When risk is evaluated to be unacceptable, risk reduction is needed and risk control 
activities must be performed. The first step is to do risk control option analysis. Risk 
control options are (in prioritized order):  
1) inherent safety by design, 
2) protective measures (in the device or in the manufacturing process), 
3) information for safety. 
The prioritized order is an important concept and can be found also from MDD. If 
possible, the manufacturer should always try to alter the design of the product in a way 
that the identified risk would reduce. When this is not convenient, some protective 
measures could be used, for example automatic cut-offs or visual and acoustic alarms. 
The least preferred option is information for safety. In practice, information for safety 
provides instructions how to safely perform a specific task or how to avoid a hazard. 
Information for safety can be, for example, a warning tag or safety information in the 
operation manual. 
Selected risk control action can reduce probability of occurrence or severity of harm 
or, in an ideal case, both. Also, often more than one action can be used to control certain 
risk. On the other hand, one possible result of the option analysis is that no practicable 
reduction option was found. In this case, risk/benefit analysis is carried out to decide if 
the medical benefits outweigh the residual risk. 
The next phase of risk control is to implement the previously selected risk control 
measures. Every implemented measure and the effectiveness of the measure should be 
verified and documented. This leads to two different verifications: the first verification 
ensures that the risk control measure is part of the final design and the second one ensures 
that the implemented risk control measure is actually effective. 
After the selected risk control measures are implemented, the residual risk shall be 
evaluated. The evaluation is based again to the acceptance criteria defined in the risk 
management plan. If the risk in question is not acceptable, further risk control measures 
must be carried out. However, if the residual risk is acceptable, the risk can be 
disregarded. 
As previously discussed, risk/benefit analysis is needed if there is no practicable 
option to reduce a certain not acceptable risk. This process step is used to analyze if the 
device provides more medical benefits than the potential harm. In most instances, the 
design should be dropped or at least altered if the related risks cannot be judged to be 
acceptable. The risk/benefit analysis may be the only opportunity for the manufacturer to 
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avoid this problem in an exceptional occasion where risk reduction is not possible. 
Standard does not provide any defined method for medical benefit estimation, so it is 
essentially a matter of experienced individual judgement. 
The implemented risk control measures should be reviewed to ensure that they have 
not introduced any new hazards or caused any unwanted side effects. This review must 
also be documented. 
The last step of risk control phase is to review the completeness of risk control. The 
object of this exercise is to ensure that all risks from all identified hazardous situations 
have been considered and covered appropriately. 
3.8. Overall residual risk evaluation 
In overall residual risk evaluation phase the overall residual risk of the medical device is 
considered from a wide perspective. Residual risk denotes the risk remaining after risk 
control measures have been taken. ISO 14971 does not define any standardized method 
for overall residual risk evaluation. The only requirement is that the evaluation is based 
on the acceptance criteria defined in the risk management plan. In this way, the decision 
how to implement the evaluation is left to the manufacturer. Nevertheless, the evaluation 
should be carried out by qualified personnel with a knowledge, experience and authority 
and the evaluation must be documented. 
3.9. Risk management report 
The last phase before commercial release of the medical device is to conduct a risk 
management report. It ensures that the risk management plan has been implemented, the 
overall residual risk is acceptable and the appropriate methods to collect production and 
post-production information are in place. The responsibility of this review is high, so it 
should be carried out by qualified person with the authority. 
3.10. Production and post-production information 
According to ISO 14971, the manufacturer must establish a system to collect and review 
production and post-production information. This information includes data generated by 
operators, users, administrators and installation accountables as well as new or revised 
laws and standards. The gathered information should be considered for relevance to 
safety. There is a possibility that some previously unrecognized hazards have emerged or 
some certain controlled risk becomes unacceptable. If this situation occurs, new 
information must be fed as an input to the risk management process and the overall 
residual risk must be re-evaluated. 
It is noticeable that national regulations might create additional requirements for post-
production monitoring. 
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3.11. Risk management process requirement extensions from IEC 62304 
As previously mentioned, the risk management process of ISO 14971 is extended by IEC 
62304 Clause 7. These extensions must be taken into account when the medical device 
software product is manufactured. The medical device software safety classification, 
declared in IEC 62304, has again a significant role in Clause 7 since only one additional 
risk management requirement is assigned to class A software. As some other important 
IEC 62304 related terms are also present, it is essential to be familiar with both of the 
standards, even when focusing only on risk management process. 
The extensions from IEC 62304 should be embedded to corresponding ISO 14971 
risk management lifecycle phase. 
3.11.1. Analysis of software contributing to hazardous situations 
The software items that can contribute to a hazardous situation should be identified. Also 
the potential causes for these contributions should be considered, for example incorrect 
or incomplete specification of functionality, software defects in functionality, unexpected 
results from unknown provenance software components, hardware failures or other 
software defects that could result in unpredictable operation and reasonably foreseeable 
misuses. If any potential causes from unknown provenance software components is 
found, those components' anomaly lists must be evaluated. 
All the potential causes and sequences of events that could result in a hazardous 
situation must be documented. 
3.11.2. Risk control measures 
Risk control measures must be identified and documented for each previously identified 
potential cause. Risk control measures can be implemented in hardware, software, the 
working environment or in user instructions.  
If the risk control measure is implemented as a part of the functions of a software 
item, the measure must be included in the software requirements, safety class must be 
assigned to the affected software item and the item must be developed in accordance with 
software development model of IEC 62304 (Clause 5). 
3.11.3. Verification of risk control measures 
Every implemented risk control measure should be verified and verification should be 
documented. If risk control measure was implemented as a software item, the measure is 
evaluated to identify any new sequences of events that could result in hazardous situation. 
The traceability of software hazards should be documented as appropriate 1) from the 
hazardous situation to the software item, 2) from the software item to the software cause, 
3) from the software cause to the risk control measure and finally 4) from the risk control 
measure to the verification of the risk control measure. 
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3.11.4. Risk management of software changes 
After software change, the change must be analyzed to determine if additional potential 
causes for hazardous situation are introduced or additional risk control measures are 
required. The change affects for existing risk control measures must also be analyzed. 
Based on these analyses, relevant previously described risk management activities are 
performed. 
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4. Agile perspective 
Agile is a complex concept with many different definitions that are related to the context 
of use. Nowadays agile is being applied in many different fields of industry, but the origin 
of the term can be found from the domain of software development. Ángel Medinilla, an 
agile evangelist and a frequent agile conference speaker, suggests that agile is, at least to 
some degree, evolution of lean that is practiced in software development [Medinilla, 
2012]. This idea seems to be coherent with the fact that most agile approaches share 
common elements with lean philosophy, either implicitly or explicitly [AAMI TIR45, 
2012]. 
The term agile is generally used when the development process in question follows 
the spirit of the Agile Manifesto, is more empirical than deterministic and is iterative and 
evolutionary. 
4.1. The essence of agile 
Manifesto for Agile Software Development was written in 2001 by seventeen software 
practitioners. In the Manifesto, Beck et al. [2001] defines four high-level value statements 
of agile software development: 
 “Individuals and interactions over processes and tools 
Working software over comprehensive documentation 
Customer collaboration over contract negotiation 
Responding to change over following a plan”. 
The left side of the value statements shows what authors consider to be more important 
than the item on the right side. It does not mean that the items on the right are considered 
to be completely unimportant [Highsmith, 2002]. 
 When further crafting the definition of agility, Ron Jeffries [2016], who is one of 
the original signatories of the Agile Manifesto, states: 
“Like many of the ideas in software development, modern 'Agile' software 
development offers to make software development more productive and 
better controlled by making it simpler. Agile is simple. Four values, a dozen 
of principles. How complex could it be? Well, it still seems to get pretty 
darn complex” 
On the other hand, agile is an umbrella term for lightweight software development 
methodologies that emerged during 90s as a counter reaction against plan-driven, heavy 
and document-focused processes that were widely used at that time [Poppendieck & 
Poppendieck, 2003]. These lightweight methodologies were, among others, Scrum, 
Extreme Programming (XP), Feature Driven Development and Crystal Clear Methods 
and they had lot of common goals and principles [Highsmith, 2002]. Afterwards, a few 
new important methods have stand out, namely Lean software development, Kanban and 
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Scrumban, a hybrid model combining Scrum and Kanban. There has also been evolution 
amongst the original lightweight methods. 
 Against this background, the term agile seems to have at least two distinct 
meanings: 
1) An ideal approach and mindset for collaborative and adaptable software 
development driven by the values and principles defined in the Agile Manifesto. 
2) A collective noun representing different lightweight software development 
ecosystems, that is, agile methods. 
For the purposes of this thesis, the first definition is applied. Rather than focusing on 
some specific agile implementation, the broader view of agile values and principles is 
examined. 
4.2. Agile principles 
The 12 principles inspired by the goals and outlined in the Agile Manifesto by Beck et 
al. [2001] are: 
1) Our highest priority is to satisfy the customer through early and continuous 
delivery of valuable software. 
2) Welcome changing requirements, even late in development. Agile processes 
harness change for the customer's competitive advantage. 
3) Deliver working software frequently, from a couple of weeks to a couple of 
months, with a preference to the shorter timescale. 
4) Business people and developers must work together daily throughout the project. 
5) Build projects around motivated individuals. Give them the environment and 
support they need, and trust them to get the job done. 
6) The most efficient and effective method of conveying information to and within 
a development team is face-to-face conversation. 
7) Working software is the primary measure of progress. 
8) Agile processes promote sustainable development. The sponsors, developers, and 
users should be able to maintain a constant pace indefinitely. 
9) Continuous attention to technical excellence and good design enhances agility. 
10) Simplicity - the art of maximizing the amount of work not done - is essential. 
11) The best architectures, requirements, and designs emerge from self-organizing 
teams. 
12) At regular intervals, the team reflects on how to become more effective, then tunes 
and adjusts its behavior accordingly. 
These principles are common to all agile development methods, but the actual 
implementation and influence of certain principle varies with the method in question. 
Each method has its own specific purpose and the fundamental nature of agile is to be 
adaptable to the context of use.  Agile aims to provide benefits in quality and correctness 
of the product, productivity and efficiency of the development process, improved 
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estimation and manageable response to change and finally product effectiveness by 
meeting the needs of customer. 
4.3. Traditional software development process 
In contrast to agile iterative process model, the traditional software development process 
can be seen as a single-pass model where all process phases should be completed as a 
whole before entering to next phase. This kind of process is commonly called a waterfall 
process model and it was first formally outlined by Dr. Winston Royce in his white paper 
titled "Managing the Development of Large Software Systems" [Royce, 1970]. However, 
it is worth to notice that in his paper Royce actually suggested iterative path to process 
through the "essential steps of computer program development" and warned that the 
single pass is "risky and invites failure" [Royce, 1970]. For some reason this idea was 
later ignored by the followers. Despite this possible common misconception, the term 
waterfall is used here to stand for traditional plan-driven software development model. 
The waterfall model, or at least its established perception, is largely criticized by the 
agile community. The infamous Chaos Report case study by the Boston-based project 
management and consulting firm Standish Group revealed that the average success rate 
of software projects was alarmingly low: only 16,2% of the projects were completed on-
time and on-budget and this rate fell to 9% in large projects [Standish Group, 1995]. The 
agile methodology aims to solve the identified problems of single-delivery waterfall 
model. 
4.4. Agile software development in medical device domain 
At first glance, the medical device standards seem to be closely following the traditional 
plan- and design-driven process model with a sequential order of phases. This is 
especially the case when considering IEC 62304 standard that describes the medical 
device software lifecycle process regulations. The plan-driven nature of the standard is 
explained by its age: the revisited 2006 version is based on the original ANSI/AAMI 
SW68 document that was published in 2001. It is worth to notice that the ISO 14971 risk 
management process has a built-in iterative loop and therefore the nature of the standard 
aligns with the values of agile more intuitively. However, the guidance for agile 
implementation is needed. 
Technical Information Report AAMI TIR45 provides recommendations and 
guidance for complying with international standards when using agile practices to 
develop medical device software [AAMI TIR45, 2012]. As it is Technical Information 
Report (TIR), it has not been a subject to the same formal approval process as a standard 
but it has been approved by a technical committee and the Association for the 
Advancement of Medical Instrumentation (AAMI) Standards Board. It is not a regulatory 
document so its recommended practices are voluntary to the user of the document. AAMI 
TIR45 provides a comprehensive list of suggestions how to align the goals, values, 
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principles and practices between agile and regulatory perspective and therefore it is 
central document when designing agile software development model in medical device 
context. 
The evolutionary software development lifecycle model of AAMI TIR45 is presented 
in Figure 5. As can be seen, the model is well aligned with the agile approach. 
 
Figure 5. Evolutionary lifecycle [AAMI TIR45, 2012]. 
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5. Synthesizing the regulatory and agile perspectives 
Regulatory framework defines a set of activities that must be performed during the 
software development process. A considerable amount of these activities must be 
documented in order to satisfy the regulatory requirements. This documentation forms an 
audit trail that is used as evidence to prove that the activity was performed in accordance 
with the quality management system. 
Following the principles of agile and lean development, the proposed software 
development model is never ready - it is continuously improving and evolving. The 
effectiveness of the model must be periodically evaluated during the retrospective 
meeting. The same applies to the quality management system if conformity to ISO 9001 
is claimed. In the medical device domain, it is usual that the quality management system 
is certified; thus, it must be periodically evaluated by a regulatory-approval body. This 
audition can be seen as a good opportunity for the organization to ensure that the quality 
management system implementation is in compliance with the regulatory framework. 
Furthermore, new ideas for further improvement targets can be gathered. 
This chapter discusses the alignment between agile and regulatory perspectives. As 
agile and regulatory perspectives are two very different models, the contextual mapping 
between the concepts is needed. A crucial aspect of regulatory development process 
construction is to thoroughly understand the goals, principles and practices of the 
regulatory framework, including all relevant regulations, standards and guidance 
documents. It is obvious that this deep understanding and knowledge is needed to ensure 
that all regulative requirements are fulfilled. 
While the main subject of this thesis is ISO 14971 standard and the risk management 
process that it defines, the general regulatory background cannot be totally excluded from 
the discussion. There are several cross-references between the relevant standards, and the 
implementation of risk management process must be consistent within the whole 
regulatory perspective. 
5.1. Mismatch between regulatory and agile perspectives 
Jim Highsmith, acknowledged thought leader in agile community and one of the original 
signatories of the Agile Manifesto, defines Chaordic Perspective [Highsmith, 2002]. It 
is a term that illustrates the nature of any organization - that there is always both, chaos 
and order, defying the use of linear planning and execution practices. This makes using 
traditional management and development processes dysfunctional since the operation 
environment is always too unpredictable. According to Highsmith [2002, p. xi], there are 
two consequences: 
1) Product goals are achievable, but they are not predictable. 
2) Processes can aid consistency, but they are not repeatable. 
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Further on, Highsmith even implies that when process repeatability increases, the project 
predictability decreases.  
Another popular model to visualize the level of complexity of management decision 
making is Stacey Matrix [2007], presented in Figure 6. In this context, the horizontal x-
axis which represents the level of certainty in decision making, is especially interesting 
as it aligns well with Highsmith’s idea. When the decision can be made based on pre-
existing information, the rational decision tactics can be used and the outcome is fairly 
predictable [Stacey, 2007]. Normally, this is not the case when developing software – the 
product is unique and no relevant pre-existing information is available and, as a result, 
the level of uncertainty increases. 
 
Figure 6. The Stacey Matrix [Stacey, 2007]. 
To address the uncertainty in decision making, the agile approach emphasizes the 
ability to respond to change and even the ability to create change in order to create value 
and competitive advantage [Jeffries, 2016]. An agile process is in a constant state of 
change. On the contrary, the regulative perspective is not tolerant towards change. For 
example, the FDA considers the changing requirement (design input) to be a sign of 
danger that the development process is not properly in control [Ståhlberg, 2015]. The 
change is also considered to be an indication of poor design. 
Agile approaches emphasise empirical and incremental development cycles. The best 
practice is considered to be the ability to frequently release small and well-focused 
features that will maximize the current customer value of the system [Jeffries, 2016]. 
Furthermore, customer collaboration and feedback has an important role in the agile 
perspective. This practice highlights the incremental and evolutionary nature of agile 
development - the requirements and even the definition of the product can evolve during 
the development process. Although the regulatory framework does not explicitly require 
a certain development lifecycle model, the mindset behind it seems to be strongly based 
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on plan-driven, linear and design upfront model. This brings some challenges for agile 
implementation. 
It is not difficult to see that the linear, single pass model is a relatively simple process 
to understand. The activities can be cleanly defined and they are completed without 
parallel tasks in a simple sequence. However, this is not the case with agile processes, 
where the same activities are completed in more complex and dynamic sequences. Robust 
change management control is essential in such a dynamic agile environment. 
One of the widely used tools in common agile development methods is self-
organizing and cross-functional teams that have total autonomy over their own processes 
and practices [Medinilla, 2012]. However, the regulatory framework requires an ongoing, 
functional and robust quality management system and disciplined processes that 
dramatically limit the freedom of choice of the development team. Concerning the 
regulatory framework, the controlled processes of the quality management system are 
essential in order to produce high quality and safe software. 
In order to demonstrate compliance to regulations, comprehensive documentation 
and collection of evidence of followed practices and process steps is needed. IEC 62304 
puts considerable interest on documentation of planning and process execution activities 
- especially the risk management process is covered with great detail, as the risk 
management process should be embedded throughout the development activities. IEC 
62304 and other regulations require a substantial amount of documentation to be used as 
audit trail, and the use of agile practices cannot be used as an excuse to discard that 
obligation.  Even if documentation is not considered to be totally unimportant in agile 
practices [Highsmith, 2002], the working software is indisputably cherished over 
comprehensive documentation - the working software is the best indicator of the project 
progress and the realized value. 
In conclusion, it is clear that not all agile values and principles are suitable when 
developing medical device software. However, it is equally evident that using traditional 
software development methods is not the most efficient way to organize the development 
process [Standish Group, 1995]. For this reason, an agile approach can bring value also 
to medical device software development [AAMI TIR45, 2012]. As the regulatory 
framework does not prohibit the use of any specific software development methodology, 
it is possible to use selected set of agile practices and tailor them to be applicable in the 
medical device context. 
5.2. Similarities between regulatory and agile perspectives 
In addition to mismatches, there are also some similarities between the agile and 
regulatory goals. One of the most apparent concept that aligns well is quality - both agile 
and the regulatory framework value high-quality software. Despite using different terms 
and emphasizing different aspects of the quality, they both clearly place high value to the 
concept. The agile perspective focuses on a broad view of meeting customer requirements 
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and fulfilling expectations with technical excellence, whereas regulatory perspective 
concentrates more on performance and safety of the product. These different aspects of 
the quality should be realised in a way that they are in good balance between each other, 
without sacrificing the safety. 
The regulatory framework does not elaborate on the efficiency of the development 
process as agile does, but this is not an incompliancy - every organization, including 
medical device manufacturers, benefit from effective development processes. The 
customer satisfaction is central value in agile perspective – the agile project has an 
implicit desire to produce a product that maximizes the satisfaction of the customer at 
every phase of the project. The customer focus is also one of the quality management 
principles as the strive to exceed customer expectations is hoped to achieve [ISO 9000, 
2005]. 
It is a common mistake to underestimate the significance of planning in agile 
methods. This phenomenon might be the result of the Agile Manifesto value statement 
which values responding to change more than following a plan. This form of statement 
makes a comparison between these two things and shows only which one is more 
important in the context of agile practices - it does not indicate that there is absolutely no 
value in the latter [Highsmith, 2002]. In fact, planning is something that happens all the 
time during agile project, on every phase of development cycle. Plans are frequently 
created and adjusted based on the feedback - it is impossible to respond to change without 
actually planning the response action before implementation. As planning is also 
important part of the regulatory framework, the value of planning is well aligned between 
the agile and regulatory perspectives [AAMI TIR45, 2012]. 
5.3. Software development lifecycle model 
Neither ISO 14971 nor the other standards of the regulatory framework mandate 
organization to use any particular development lifecycle model. However, IEC 62304 
requires that some certain lifecycle model is chosen and the implementation details are 
documented within the quality management system [IEC 62304, 2006]. This leaves the 
manufacturer considerable amount of freedom for lifecycle model design and 
implementation. 
The standards describe various activities that must be performed within the software 
development lifecycle. The activities can have distinctive requirements, completion 
criteria and cross references between each other. In IEC 62304 these activities are 
organized in a manner that to a large extent resemble linear waterfall development cycle. 
However, the agile approach is indeed feasible if the organization carefully documents 
the lifecycle design and implementation details [AAMI TIR45, 2012]. Especially close 
attention should be paid to documenting the timing and sequence of the activities and the 
audit trail of the accomplished tasks. The lifecycle model and risk management process 
integration should also be in the centre of attention. 
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5.4. Dividing the regulatory process activities to different layers of abstraction 
One practical solution suggested by AAMI TIR45 [2012] for agile and regulatory 
perspective alignment is to divide the regulatory process to different layers of abstraction. 
Certain regulatory activities are completed only once during the lifetime of the 
development process while the others are carried out repeatedly. These activity types are 
divided into different abstraction layers. This practice is very useful in the context of risk 
management process.  
 
Figure 7. Mapping IEC 62304’s activities into agile’s incremental/evolutionary 
lifecycle [AAMI TIR45, 2012]. 
As seen in Figure 7, the layers of abstraction are derived from agile practices. In the 
figure, the sequential process model phases of IEC 62304 are mapped with agile 
incremental lifecycle. The most abstract layer or context where regulatory development 
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activities are completed is project or product layer, depending on the type of the 
organization and the development environment. These activities, typically planning and 
design tasks, are related to the whole project or product. For example, risk management 
plan must concern the whole project and it must be produced and validated before any 
actual development has begun. 
The second layer is related to each release or version of the product. The regulatory 
activities belonging to this layer are typically verification measures where the quality of 
the release is verified. Following the mindset of agile practices, a release is a pre-planned 
and coherent set of value-focused features. The release can be made based on one or more 
increments. 
According to AAMI TIR45 [2012], the third layer is increment layer. The term is 
relative to applied agile convention, thus the iteration layer is equally suitable term. The 
result of each increment should be potentially shippable product. The requirement to 
produce potentially shippable product is useful mindset since it creates high level of 
confidence that all work done in the increment is actually finished. The decision whether 
to create a release to be deployed to the production environment or not can be made based 
on the evaluation of that time. It is fairly usual that the result of one increment does not 
bring enough value compared to costs of the deployment, especially in the cases where 
the development cycle is relatively short. However, if this scenario is frequent, it is a 
strong evidence that the deployment process is too ineffective and should be investigated 
and presumably improved. The project delivers value only when deployed and the best 
value comes from small and focused features [Jeffries, 2016]. 
From the viewpoint of regulatory requirements, the only actual difference between 
the release layer and the increment layer is the required ceremonies of the release activity. 
In the context of risk management process, this includes the activities of the overall 
residual risk evaluation and producing the risk management report. It is debatable if the 
division between release and incremental layer should be highlighted or even initially 
made. One central concern related to this practice is that the release ceremonies, which 
are not frequently performed, will increase the length of the feedback cycle of those tasks. 
For example, if the residual risk evaluation is done not until the end of planned release 
cycle, the unexpected findings can postpone the release schedule. Similar problems might 
occur during the risk management report processing. Besides the feedback cycle of the 
release ceremonies, the feedback cycle of the end user feedback also increases. This effect 
has several drawbacks that agile practises are trying to address - the short feedback cycle 
is essential agile principle. The short feedback cycle improves the quality of the software 
[Highsmith, 2002] and the frequent deliveries make the project more predictable [Jeffries, 
2016] - the level of unexpected and considerable problems will decrease. 
In the context of risk management process, the residual risk evaluation can be 
performed simultaneously with the development during the iteration and the composing 
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of the risk management report can be automated using the data from the risk management 
tool. These approaches are highly recommended. 
The last abstraction layer is the story layer. The agile term story represents a small 
piece of functionality that can be an incomplete set. Depending on applied agile 
convention, also term use case could be used. From the regulatory perspective, story is 
the smallest reasonable process management item that is addressed in the requirements 
[AAMI TIR45, 2012]. The layers and the corresponding process activities are presented 
in Table 1.  
 
Table 1. Process activities in different layers.  
Layer Process activities 
Project layer  project development planning 
 high-level requirements analysis 
 infrastructure and architectural 
design 
Release layer  release planning 
 integration 
 integration testing 
 system testing 
 regression testing 
 release 
Increment layer  increment planning 
 integration 
 integration testing 
 system testing 
 regression testing 
Story layer  story planning 
 story requirements analysis 
 design (as needed) 
 implementation and verification 
 integration 
 integration testing 
 system testing 
 
5.5. Definition of value in medical device development context 
Agile does not especially emphasize the importance of software safety or seek benefits 
by improving it. However, agile emphasizes the concept of customer value and 
concentrates on maximizing the value at all times during the software development 
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lifecycle. From the viewpoint of medical device software customers and stakeholders, 
safety is arguably the highest valuable quality of any medical device product [AAMI 
TIR45, 2012]. Thus, the agile concept of value can be redefined in the context of medical 
device followingly: 
1) Safety of the use of the medical device. 
2) Medical benefits of the medical device. 
3) Other customer value that provides competitive advance over the similar 
products in the market. 
This definition applies to the whole end product as well as every separate feature of it. 
This definition of value must be taken into account in every step of the development 
process design and also in product design itself. It is a very useful definition especially 
during the development phase when prioritizing the product features in product backlog. 
With the respect to agile perspective to value, it must be noted that value will be realized 
only when product is shipped and put to use. 
5.6. Definition of done as a tool to fulfil the regulatory requirements 
Definition of done is a very important concept in agile practices. It is a collaborative tool 
to ensure that all team members agree what "being done" means in different development 
activities. Definition of done is trying to address the problem of partially done work. 
Partially done work causes several problems: it has tendency to become obsolete, get in 
the way of other development and it causes uncertainty if the feature is working at all, or 
if it is a working solution to the business problem it tries to solve. Partially done work 
ties resources and thus generates financial risk. The elimination of partially done work is 
a project management risk-reduction strategy [Poppendieck & Poppendieck, 2003]. 
For example, definition of done can intend that the feature is designed, implemented, 
integrated, documented, tested and validated. Kniberg [2015] has a very practical 
approach when he states that the best possible way to define done is to intend that the 
feature is "ready to be deployed to production". On the other hand, he also admits that 
not all types of stories are able to follow this convention. He suggests that if this is a 
problem, definition of done could be defined separately for every story. Development 
team can use checklists as a backup for common sense. The specific items selected to be 
in the checklist will depend on the type of the feature, technologies used and other current 
impediments of the project [Rubin, 2012]. 
Jeffries [2016] emphasizes the evolving nature of definition of done. To summarise 
his theory, evolving nature of the term means that at the beginning of the project the 
definition can be loose but it gets more stringent over time. For example, there might be 
some actual project related impediments that prevent the features be production ready at 
the end of the increment and when these impediments are later removed, the definition 
of done can evolve. While this approach seems practical and natural in agile perspective, 
it does not utilize the full potential of the concept regarding the regulatory framework. 
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Definition of done is a very useful concept when aligning the regulatory and agile 
perspective. It can be used to illustrate the regulative process requirements that must be 
performed before a certain issue or story is completed. When used in this manner, it is 
functioning as a risk management process related acceptance criteria to ensure that all 
risk controls are implemented and verified - if definition of done is used consistently with 
every feature, story, use case, backlog item, increment and release. It can ensure the 
completeness of risk control (however, this approach should not be confused with the 
item-specific acceptance criteria, which is a set of conditions of business satisfaction for 
that specific feature). Furthermore, appropriate audit trail must be generated during the 
process in order to satisfy the requirements of the regulatory framework. In addition, 
automate acceptance tests should be used to protect the features not become undone at 
some later point of time during the development project. 
5.7. Process inputs and outputs 
The regulative framework emphasizes the importance of process inputs and outputs. 
When evaluating the efficiency of the process, it is possible to determine how well the 
planned process output meets the process input. In linear model these concepts are easy 
to understand and thus fairly convenient abstractions. The problem with the linear model 
is that it resembles the traditional waterfall development model and thus is not very well 
suited for software development in a complex domain – the agile approach is more 
practical solution. However, the dynamic nature of the agile process adds complexity to 
the way in which inputs are used and outputs are generated [AAMI TIR45, 2012]. 
In the linear model, it is easy to follow the process flow: the process is started with 
the inputs and the process produces the outputs. In the incremental development this flow 
is less apparent. In agile development, it is extremely important for every process to 
define the possible inputs, the entry criteria of these inputs and how ready the inputs 
should be before the process starts. Similarly, it is essential to define the types of the 
possible outputs, the exit criteria of these outputs and how ready the outputs should be 
before process can be regarded as done. 
The agile approach gets complicated especially with design inputs and outputs. 
Design inputs can be defined as the physical and performance requirements that are used 
as a basis for device design and design outputs as the result of design effort (at each 
design phase and at the end of the total design effort). With respect to this definition, a 
design input can be for example a story, a use case, a user need, a functional and non-
function requirement and intended use of the device. Equally, the concrete design output 
can be the design artifact that demonstrates that design process has been completed, that 
is, the design itself. 
In an agile perspective, the relationship between the inputs and outputs is not linear, 
it is bidirectional - in the iterative process new information is gathered and part of the 
output affects to the input through the feedback cycle. This denotes that the inputs can 
 33 
change during the activity process, at the same time while the outputs are being produced. 
Therefore, the relationship between the inputs and outputs should be considered in a 
context of small pieces of information. 
It is important to notice that large amount of the design input can be verbal 
communication between the development team and the customer and this communication 
can last over the whole development phase. When considering a certain activity, the scope 
should be defined and the minimum amount of relevant input selected. To be able to start 
the activity, the inputs should ready enough to allow proceeding [AAMI TIR45, 2012]. 
If there exists a regulatory requirement to get an approval or validation for the input 
before proceeding, the validation task should be documented and included in the process. 
Naturally, it is important that the process implementation demonstrates that the regulatory 
requirements have been satisfied. 
IEC 62304 standard elaborates the concept of inputs and outputs with great detail. 
Similarly, AAMI TIR45 technical report provides high quality guidance for this fairly 
complex issue. The closer analysis of the subject is out of the scope of this thesis. 
5.8. Rationale behind agile methodology adaptation  
While agile itself does not provide full functioning processes for software development, 
certain agile development methods can give detailed guidance for development activities. 
The problem with predefined and exact processes is that every organization, 
environment, project and team is different - the processes need to be modified to fit the 
domain. The agile perspective emphasizes the need for tailoring the development 
methods to fit for the special context where used and the same applies to regulatory 
perspective [AAMI TIR45, 2012]. In order to design an effective agile development 
method implementation, it is essential to understand the underlying principles and values 
of the practices. As Kent Beck says in his foreword of Lean From The Trenches: 
"Applying those practices required wisdom, patience and persistence, which is why you 
can't just copy the story to fix your project" [Kniberg, 2011]. The organizations should 
understand the values and practices of the agile development first, and only after that find 
the necessary processes and tools to support the vision. It is important to adapt to reality, 
not try to make the reality adapt to vision [Medinilla, 2012]. 
The speciality in medical device domain is that it requires considerable amount of 
methodology ceremony to meet the regulatory requirements. There is no commonly 
known existing agile method that would offer sufficient discipline in its processes so 
adaptation is inevitably needed. This should not be seen as a problem, since the basic 
nature of agile is to be adaptable. However, the well-documented set of best practices of 
a certain agile methodology can help organization to learn and understand the principles 
and values of agile software development [Medinilla, 2012]. 
When designing the agile method implementation, the project objectives and 
characteristics should be carefully analyzed. Besides business-value-oriented objectives, 
 34 
Highsmith [2002] has found four related project characteristics: 1) team size, 2) project 
criticality, 3) risk and uncertainty and 4) activity scope. The team size effects on suitable 
communication practices, also the location of team members must be taken into 
consideration. Highsmith suggests that the criticality of the project could be simplified to 
the question: can software failure threaten life? However, this seems to be 
oversimplification from the viewpoint of medical device regulations, where medical 
device safety classification controls the applicable quality management requirements. 
Naturally, risk and uncertainty characteristics are related to project criticality, but 
Highsmith uses these terms to describe the volatility of the project. Finally, the activity 
scope describes the limits of the development model lifecycle - which activities are 
defined to be in the lifecycle of the model and which are defined to be out of the scope. 
For example, the activity scope in medical device domain is fairly wide on account of 
regulatory requirements that must be fulfilled within the development model. 
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6. Towards a reference implementation model 
The proposed reference implementation model is presented in this chapter. The idea of 
the reference model is not to cover every aspect of an agile methodology. Instead, the 
intention is to present concrete ideas how the risk management process regulatory 
requirements can be fulfilled by using commonly known best practices of agile 
perspective. The model is a small set of easily understood conventions.  
The implicit nature of regulatory and agile perspective is to be adaptable to the 
specific context of use, thus the development process model and the risk management 
process should always be tailored for organizations individual needs. With respect to this, 
the reference implementation model is not excessively specific about the implementation 
details and thus can be applied to all organizations that wish to claim conformity to ISO 
14971.    
The general agile terminology used in this chapter is derived from AAMI TIR45 
[2012] where applicable. As AAMI TIR45 does not cover the whole scope of agile 
perspective, certain terms are also derived from two of the most commonly used agile 
frameworks, Scrum and XP [VersionOne, 2015].  
6.1. Basis of the model design 
Arguably the most important goal when designing the risk management implementation 
model is to ensure that the model is in compliance with ISO 14971 and with the other 
relevant standards. The scope of this thesis is limited to ISO 14971, but the 
implementation is not practicable or useful if it is conflicting with the other parts of the 
regulatory framework. For this reason, special focus is given to ensure that the 
recommendations and ideas provided in this thesis are not conflicting with the other 
requirements of the regulatory framework. 
On the other hand, from the agile perspective, the product that is compliant but is 
never delivered to the customer produces no value. Thus the primary goal of the 
development is to produce working yet safe product. In conclusion, this primary goal of 
delivery is actually supported by the secondary goal of compliance - both are needed to 
satisfy the business requirements of medical device domain. 
The most efficient way to implement risk management process is to integrate it into 
the overall product development process [Schmuland, 2005].  
6.1.1. Adding value with lightweight risk management process 
When considering the implementation of ISO 14971 in compliance with agile principles 
without prior experience, it is easy to make a hasty conclusion and to view the 
requirements of the standard as a burdensome and extra work. For this reason, it is 
extremely important to design the development process in a way that only the absolutely 
required regulatory tasks are added. Furthermore, the implementation of these tasks 
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should be as lightweight as possible and, at the same time, they should be implemented 
in which way they produce maximum value to the development team.  
Schmuland [2005] states that risk management, if done properly, can powerfully 
complement the overall development process by improving its ability to identify the 
factors that can fail to meet the customer requirements. However, it is unfortunately 
common to overreact and create particularly detailed process that cannot be practically 
followed. According to Schmuland, the value-added risk management process consists 
of three fundamental factors:  
1) The intent of process is not lost in the details and process is not impractical. 
2) Process deliverables actually add value. 
3) The people performing the risk management activities must have a sense of 
unity and common interest towards the process goals. 
The nature of the software development is not similar that manufacturing production 
where large quantities of same product is reproduced and where detailed process is the 
most efficient option. The nature of the software development resembles craftsmanship 
more than a static manufacturing assembly line [Hunt & Thomas, 2000]. Consequently, 
too detailed process reduces the focus on essential activities, thus every process step 
should produce value.  
The value-adding process implementation is one of the most important design goals 
and principles when aligning the agile and regulatory perspectives, thus it is a basis of 
the implementation model design. It is essential to find a right balance point where 
business and regulatory goals are met.  
6.1.2. Necessary compliance 
Highsmith [2004] introduces the concept of necessary compliance. According to 
Highsmith, there are good reasons for some compliance activities - the medical device 
regulatory framework certainly being one of them. Highsmith even suggests that every 
organization has legitimate compliance reasons. When these reasons are present, they 
must be kept from impeding the development process since usually these compliance 
activities are not producing customer value. On the contrary, they are the cost of doing 
business in the selected domain [Highsmith, 2004]. The concept of necessary compliance 
is a strategy to do compliance activities just enough, but no more than is absolutely 
required - they are considered to be overhead and thus subject to minimization. 
When following the ISO 14971 standard, certain fundamental regulative 
requirements must be satisfied. The risk management system must be present during the 
whole lifecycle of the medical device [AAMI TIR45, 2012]. As the risk management 
process of ISO 14971 is part of the quality management system, the quality management 
system must also be present. In practice, this means that the quality management system 
must be implemented in compliance with ISO 13485 and it must be properly understood 
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by the organization. The maturity of the quality management system implementation 
must be at adequate level to be effective and controlled. 
The agile values and principles of the development process can be fulfilled only 
without compromising the requirements of the regulatory framework. According to 
AAMI TIR45 [2012], agile must meet the requirements of the quality management 
system. Agile can adapt, whereas the minimum requirements of the regulative framework 
cannot. 
6.1.3. Supportive project management tool and documentation 
In practice, some supportive project management tool should be used to track both the 
development issues and the risk management tasks. According to VersionOne State of 
Agile Survey Report [2015], the most popular tool used in agile project management was, 
quite surprisingly, Microsoft Excel. While Excel can undoubtedly be useful tool when 
calculating estimations and designing releases, it has certain limitations regarding to 
ability to produce project documentation.  
When following regulations, the agile project management tool is needed to produce 
evidence that risk management process has been followed as defined in the risk 
management plan. For the solution to be as lightweight as possible, the risk management 
process flow should be embedded into the development process flow and the selected 
tool should support this practice. For example, the second popular agile project 
management tool by the VersionOne survey [2015], Atlassian JIRA, offers these features 
as built-in. In addition, several other suitable tools exist in the market. 
Besides producing evidence about followed practices, the project management tool 
is useful also in other ways. It can be used to bring discipline to a development work by 
guiding the team to follow the preferred process and workflow. In this way, the process 
is visible to the whole team and other interest parties. If the information security policy 
allows, some up to date views can be revealed to the customer, which further improves 
the visibility of the project. Furthermore, the project management and issue tracker tool 
can be used as a primary documentation tool of the project.  
Agile values “working software over comprehensive documentation” [Beck et al., 
2001]. With respect to this value statement, the documentation produced during the agile 
project should be valuable to the development team. When properly using correct project 
management tool, the documentation is semi-automatically generated by the tool during 
the process – it is a byproduct of the development process. Similarly, certain software 
design related documentation can be automatically generated from the source code and 
executable specifications itself can document the business requirements of the product at 
the same time while being automated tests. Regardless of the origin, the documentation 
must meet the requirements of the regulatory framework and it must be understandable 
for regulators [AAMI TIR45, 2012].  
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6.1.4. Focus on safety by team collaboration  
ISO 14971 defines that risk management activities may be carried out only by the 
personnel with appropriate training. In addition, these persons must be named in the risk 
management plan. This can become a bottleneck for the development process if risk 
management activities block the development, or management problem if the risk 
management activities are carried out in a late phase of the development. Therefore, it is 
important that risk management activities are done simultaneously and parallel with the 
software development.  
A practical approach is that every member of the development team has an 
authorization to identify potential hazards at any phase of the development by entering 
the findings to the management tool, but only the trained members are allowed to do 
further analysis. It is important to notice that the requirement for training in this context 
is related particularly to risk management, in contrast with the technical aspects of the 
development. As a result, the person carrying out the risk management activities might 
need consultation about the technical details from other members of the development 
team. 
6.1.5. Commitment through understanding 
Regardless of the details of the development model implementation, the team must be 
trained to understand the basic fundamentals behind the model design. The model and 
the processes cannot function optimally if the development team is not fully committed 
to follow and endorse them. As noted in the previous chapter, from agile perspective the 
team owns its processes and workflows. This idea should be cherished even when the 
risk management requirements must be met. The team needs to understand also the goals 
and values of the risk management system in order to be able to continuously improve 
the development process while, at the same time, taking responsibility for the regulatory 
scope. This aim is supported by the common agile practice of collective ownership of 
design, code and tests. With collective ownership, the expertise is distributed throughout 
the whole team [AAMI TIR45, 2012].  
It is important to notice that ISO 13485 requires development team members to be 
trained in their tasks and this training activity must be documented. The practices of 
collective ownership, pair working and peer review can be effective when fulfilling the 
regulatory requirements.  
6.1.6. Executable requirements 
The agile practice of executable requirements is a procedure where product requirements 
are written in formal, domain specific language and can be executed as automatic tests to 
ensure the correct functionality of the product. This technique has a straight relationship 
to acceptance test-driven development methodology but it is not a direct synonym.  
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The concept Specification By Example (SBE) was introduced by Gojko Adzic [2011] 
and it is recommended by Kniberg [2011]. It is a set of practices and process patterns to 
implement agile acceptance testing and behavior driven development and to bridge the 
communication gap between business stakeholders and development team. The main aim 
of SBE is to ensure that right software product is delivered effectively and SBE promises 
to provide just enough documentation at the right time and to improve the quality of the 
software product. Furthermore, a living documentation system will be generated by 
following the SBE practices. Overall, SBE is compelling approach for agile executable 
requirements implementation. 
Executable requirements will make the process of validating the software system 
cheap and efficient. The validation can be made repetitively during the development 
which decreases the feedback delay. The main difference between executable 
requirements and traditional unit and functional testing approaches is the business focus 
– the requirements are written as business requirements and, as a result, are accessible 
also to business users [Adzic, 2011]. In practice, system specifications are described with 
concrete examples that can be used to validate the functionality of the system. These 
specifications are automated and used as an executable acceptance test. The executable 
requirements are written collaboratively and can be maintained by every member of the 
development team.  
Executable requirements must be frequently validated and updated to obtain the full 
benefits of SBE [Adzic, 2011]. During the development project, the domain knowledge 
of the development team deepens and the requirements must be updated to reflect these 
changes. This procedure ensures that the software is always behaving as expected and 
specified. Furthermore, executable requirements form an authoritative and reliable source 
of information that is easy to read and understand [Adzic, 2011]. The artifact of 
executable requirements is genuinely living documentation and important part of the 
delivery process.  
In order to be used as a part of final requirement documentation, the executable 
requirements must be clear enough to be understood by the regulators. To facilitate 
readability, the requirements should focus the scope on to business requirements and use 
domain specific and ubiquitous language [Vernon, 2016]. The regulatory requirements 
do not prevent the use of executable requirements as a part of requirement documentation 
[AAMI TIR45, 2012].  
6.1.7. Requirements as use cases 
User story or plainly story are terms commonly used in agile practices to describe a 
lightweight requirement of certain functionality or feature that creates business value. 
Accordingly, term story is used also in AAMI TIR45 [2012]. A common format for user 
story is to define the user role, to describe the user goal and to explain the benefits 
achieved [Cohn, 2004]. The fact that the concept of story is used in AAMI TIR45 
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indicates that story should be suitable tool to be used in regulated environment. However, 
more formal approach of use case can produce some additional benefits.  
Alistair Cockburn [2001] has created a template that addresses the different aspects 
of use case requirements in a comprehensive manner. According to Cockburn, the 
template is adaptive and can be tailored by the unique needs. Even though the template 
is fairly detailed and not particularly lightweight format, it is an excellent introduction to 
the approach. However, Jacobson et al. [2016] has further developed the concept to 
include newer related ideas making use cases to be well-suited for regulatory 
environment.  
According to Jacobson et al. [2016], use cases includes all the techniques provided 
by the stories. Besides telling user stories, they offer more. For example, they offer 
support for architecture, design, test and user experience.  Jacobson et al. defines six basic 
principles for use case adoption [2016, p. 63-64]:  
1) Keep it simple by telling stories 
2) Understand the big picture 
3) Focus on value 
4) Build the system in slices 
5) Deliver the system in increments 
6) Adapt to meet the team’s needs 
The analysis of the Use Case 2.0 of Jacobson et al. reveals that the stories used in agile 
practices are actually included in the use cases as narratives with additional relevant 
information. This information includes, for example, relation to the big picture of the 
system, better organization of test assets, test-case generation and analysis, active scope 
management and easier identification of missing functionality. Furthermore, use cases 
undergo several state changes with respect to concurrent development cycle and the 
different use case slices progress in parallel and actually drive the development system. 
The set of all use cases forms the functional requirements of the system and can also be 
used in applications that are not user-intensive [Jacobson et al., 2016].  
The characteristics of Use Case 2.0 as defined by Jacobson et al. are ideal from the 
viewpoint of the regulatory framework. Therefore, the concept is adopted to the reference 
implementation model.  
6.1.8. Testing and verification 
While test planning is not central issue in agile development, it is very important activity 
in regulatory perspective. Agile testing is done in different phases of the development 
cycle; therefore, it is crucial to plan testing carefully and to document these plans 
accordingly.   
In agile practices, testing is used to ensure the correctness of the system and as a 
method to provide instant feedback during development. In practice, testing should be as 
automated as possible in order to enable efficient regression testing. In incremental 
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development model, efficient regression testing is needed to demonstrate the correctness 
of the software version that is going to be released [AAMI TIR45, 2012]. Besides the 
new features added, the previous features must also be verified. From the viewpoint of 
the regulatory framework, tests are as important as the actual code since every use case 
that gets implemented must also be verified. The practical method to make certain that 
use cases will be entirely tested is to use test-driven development and write automated 
tests in different abstraction levels of the system. The test results must be documented as 
evidence to prove that testing and verification activities are performed as planned.  
To ensure that every requirement is verified, the requirement must be linked to 
verification record. When tests are used as a tool to provide verification, the test results 
must be traceable back to the requirement. The process to write and run tests is integrated 
to use case implementation process and can be controlled by definition of done -
convention. As a result, traceability will be built-in to development process.  
6.2. The essence of risk management process 
As previously discussed, in order to be able to perform risk management activities 
efficiently it is important to understand the primary rationale behind the process. The 
main goal of the regulatory framework is to protect society against unsafe medical 
devices. With respect to this, the most important goal of the risk management process is 
to gather knowledge about the risks related to the product and to control the overall 
residual risk before releasing the device to production use.  
In practice, the process model of ISO 14971 can be roughly divided to two parts: to 
activities that are performed during product development and to activities that are 
performed after development [Schmuland, 2005]. Naturally, this division is not that 
evident when following agile practices since the development phase and the phase after 
release are actually overlapping with each other. Table 2 presents all requirements for 
documentation related to medical device software risk management process.  
With respect to agile philosophy, the risk management process should be transparent 
during the whole product development. This practice ensures that the possible safety 
issues are visible from the beginning and no risk related surprises emerge at the end of 
the development cycle. In addition, top management representative should be actively 
present in the risk management decision making during product development. This is 
important since the risk acceptability level is defined by the top management in the risk 
policy and should be endorsed accordingly. 
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Table 2. Requirements for documentation from ISO 14971 and IEC 62304. 
Standard 
 
Clause / 
Subclause 
Requirements for documentation 
ISO 14971 3.1  risk management process 
 3.2  policy for determining criteria for risk 
acceptability 
 3.3  qualification records of persons performing risk 
management tasks 
 3.4  risk management plan (including changes) 
 3.5  traceability for each identified hazard to 
o risk analysis 
o risk evaluation 
o implementation and verification of the risk 
control measures 
o the assessment of the acceptability of 
residual risk(s) 
 4.1  implementation of the planned risk analysis 
activities 
 result of risk analysis 
 4.2  intended use 
 reasonable foreseeable misuse 
 other characteristics related to safety 
 4.3  known and foreseeable hazards (in normal and 
fault conditions) 
 4.4  hazardous situation(s) 
 risk estimations 
 system used for 
o qualitative or quantitative categorization of 
probability of occurrence  
o categorization of severity of harm 
 5  results of risk evaluation 
 6.2  selected risk control measures 
 6.3  verification of each implemented risk control 
measure 
 verification of effectiveness of each implemented 
risk control measure 
 6.4  residual risk evaluation 
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 6.5  results of risk/benefit analysis (if performed, 
should generally be avoided) 
 6.6   review of the (unwanted) effects of the risk control 
measures 
 6.7  completeness of risk control 
 7  evaluation of overall residual risk acceptability 
 8  risk management report 
 9  evaluation of risks arising from production or post-
production 
IEC 62304 4.3  software safety class assigned to software system 
 rationale for using lower software safety class for 
a certain software item (lower than the overall 
system) 
 7.1  potential causes of software item contributing to a 
hazardous situation 
 sequences of events that could result in a 
hazardous situation (for each software item) 
 7.2  risk control measures defined (for each software 
item) 
 7.3  evaluation of risk control measures implemented 
as software item (to identify new hazards) 
 9.5  problem reports and their resolution and 
verification 
 
Schmuland [2005] has found four principles encountered when performing risk 
management activities: 
1) All hazardous situations cannot be avoided. However, exposure to certain 
hazardous situation does not necessarily result in harm. 
2) The severity and type of harm can vary within a certain harm occurrence. 
3) Risk controls can limit the probability and/or severity of the possible harm. 
Nevertheless, all risk controls are imperfect and thus can fail. 
4) Regarding the safety of the product, the overall residual risk is the most 
important factor over each individual harm scenario. 
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Figure 8. Essential product-development risk-management process [Schmuland, 2005]. 
As can be seen in Figure 8, not all harm scenarios need to be controlled. If the risk is 
evaluated to be acceptable, risk reduction is not needed and that specific harm scenario 
can be disregarded. However, even if the risk reduction is not needed from the regulatory 
viewpoint, there are no barriers to implement risk control measures, if judged to be 
suitable, outside of the risk management process. Naturally, it is only reasonable to try to 
reduce the risks to the lowest level practicable. It is possible to also include this approach 
to risk management process, ISO 14971 Annex D.8 provides guidance for appropriate 
implementation [ISO 2012].  
Schmuland [2005] emphasizes the importance of certain characteristics of persons 
performing a successful risk management activities. First, product understanding is 
needed in order to understand the potential harm scenarios and suitable solutions. Second, 
advocacy is needed to be able to use good judgment when considering the right balance 
between business interest and patient interest. Finally, passion should be present to 
actively and honestly seek safety improvements, instead of just focusing to satisfying the 
regulatory agencies.  According to Schmuland, this mindset will eventually lead to 
quality improvements and consequently to competitive advance in the market.  
6.3. Risk management activities preceding the development phase 
Certain amount of risk management activities must be performed before the active 
development phase. In regulated perspective, the software development planning is 
formalized activity and it must be documented accordingly. During software 
development planning, the risk management planning should also be conducted. The risk 
management planning should consider all the items that are required in the risk 
management plan.  
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Special attention should be given to risk acceptability criteria definition as the risk 
acceptability definition has a substantial impact to rest of the risk management process – 
the risk acceptability eventually decides the overall effectiveness of the risk management 
process [ISO, 2012]. As the ISO 14971 does not define the acceptability level, the 
decision is left entirely to the manufacturer. The possible methods determining 
acceptability level are, amongst others, to seek further guidance from applicable 
standards for that specific type of medical device, to use information from similar devices 
as a reference and to evaluate data from clinical studies. In addition, certain type of risks 
can be a matter of general interest thus additional weighting should be given to meet the 
expectations of public opinion. The acceptability level can be presented in a risk matrix.  
 
Figure 9. Example of qualitative 3 x 3 risk evaluation matrix [ISO, 2012]. 
Risk acceptability criteria for software-caused or software-controlled risks can differ 
from the matrix presented in Figure 9 as the probability of the harm cannot be estimated. 
In this case, the estimation is based solely on the severity of the harm [IEC, 2009].  
Finally, system to collect evidence from performed risk management activities and 
to enable traceability from identified hazards to controlling risk control measures is 
required. The ISO 14971 term for this system is a risk management file and also this 
document can be embedded into the quality management system. As the software is a 
subject of constant change during the development, also the risk management file can 
change. In this case the risk management file must be versioned accordingly.   
6.4. Medical device software risk estimation considerations 
ISO 14971 requires that the risk management activity of risk estimation must be carried 
out, but it does not define the method how it should be performed. Risk estimation can 
be qualitative or quantitative and it is analysis of two distinct components: the probability 
of the occurrence and the severity of possible consequences. The estimation is based on 
available information or data. According to ISO 14971, the information and data be 
obtained, for example, from: 
1) published standards, 
2) scientific technical data, 
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3) field data from similar medical devices already in use, including published 
reported incidents, 
4) usability tests employing typical users, 
5) clinical evidence, 
6) results of appropriate investigations, 
7) expert opinion, 
8) external quality assessment schemes. 
Besides being a product of multiplication of probability of the occurrence and severity of 
the harm, the risk estimate can also be described differently, for example with two-
dimensional risk chart [ISO, 2012].  
The difficult in the estimation is that every hazardous situation is different. The 
systematic way to do estimation is needed.  
6.4.1. Probability estimation 
Quantitative categorization of probability level is recommended when suitable data is 
available. If data is not present, qualitative description should be given. Manufacturer can 
decide how many probability levels is needed, but at least three levels should commonly 
be used. The categories should be clearly defined in order to avoid misunderstandings 
and confusion. When evaluating the probability, circumstances and the complete 
sequence of events leading to harm should be considered - the concept of exposure is in 
central position. Seven approaches of ISO 14971 to probability estimation are:  
1) use of relevant historical data, 
2) prediction of probabilities using analytical or simulation techniques, 
3) use of experimental data, 
4) reliability estimates, 
5) production data, 
6) post-production information, 
7) use of expert judgment. 
From these approaches, the first three are complementary and have different strengths 
and weaknesses. It is recommended to use as many approaches as convenient since 
multiple iterations will increase the reliability of the results. The expert judgment should 
be used only as a last resort if none of the others are sufficient.  
As can be seen in Figure 3 from Section 3.1, the probability of occurrence of harm 
consists of two components: probability of a hazardous situation occurring and the 
probability of a hazardous situation leading to harm. The original figure (Figure E.1 in 
ISO 14971) is not included in the main part of ISO 14971, instead it is located in Annex 
E. Therefore, it is possible that certain risk management process implementations are 
realized without using this division.  
The reliable probability estimation can be made when suitable data is available or 
when reasonable qualitative estimate is possible. However, this is not always the case, 
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there are certain situations where reliable estimations are particularly difficult to make. 
IEC [2009] states that there is no consensus for method of estimating the probability of 
occurrence of software failure. When the probability estimation cannot be reached, the 
risk should be evaluated on the basis of the harm alone. If the hazard is minor without 
significant consequences the risk can be judged to be acceptable. On the other hand, if 
the hazard has notable outcomes, the probability estimation should be based on a 
reasonable worst-case estimate. This means, in practice, that the risk control measure 
must prevent the harm scenario entirely or reduce the severity of the harm to acceptable 
level.  
IEC [2009] states:  
“Although it may not be possible to estimate the probability of the 
occurrence of a software failure, it is obvious that many RISK CONTROL 
measures reduce the probability that such a failure would lead to a 
HAZARDOUS SITUATION.” 
Although the probability estimation cannot be given before or after the risk control 
measure implementation, it is evident that the probability of certain hazardous situation 
can reduce. The manufacturer shall demonstrate the effectiveness of the implemented risk 
reduction measure in order to prove that the risk acceptability level is achieved.  
6.4.2. Severity estimation 
The severity level categorization should be descriptive and based on a product 
characteristics. Manufacturer can decide how many categories is used and how they are 
defined. It is important that they do not include any element of probability and they are 
valid in clearly defined use conditions [ISO, 2012].  
6.4.3. Overall residual risk estimation 
Overall residual risk is combined impact of all the residual risks that still exists after risk 
control measures have been implemented. The overall residual risk can exceed the limit 
of acceptable risk even if individual residual risks do not. The high number of identified 
risks and the complexity of the system can increase the overall residual risk [IEC, 2009]. 
All risk control measures must be implemented before residual risk estimation.  
Schmuland [2005] suggest that the overall residual risk estimation should be 
quantitative. In practice, quantitative estimation is the expected number of injuries for 
each of the specified harm over the whole lifecycle of the product - if the product is 
released with associated harm scenarios, it is only realistic to expect harms to occur with 
definite quantity. The quantitative estimation has certain benefits over qualitative 
estimation. First, quantitative estimation can be used as a benchmark to validate the 
effectiveness of the quality management system. Second, quantitative estimation can also 
be used to validate field performance of the device after the release, whereas qualitative 
estimates cannot be added afterwards to be compared to actual results. Finally, the 
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quantitative estimation is less abstract than qualitative, therefore it is effective method 
for clarifying and visualizing the risks related to the product.  
6.5. Medical device software risk control considerations 
If identified risk is evaluated to be unacceptable based on the criteria defined in risk 
management plan, risk control measures are needed. The evaluation is based on the 
acceptance criteria defined in risk management plan.  
The suitable risk control measures must be identified for software requirement and 
software failure related risks. The suitable measures can increase detectability, reduce 
severity and/or reduce the probability of a hazardous situation [IEC, 2009]. It should be 
noted that the most effective risk control measure is the one that eliminates the harm 
scenario altogether. As defined in ISO 14971, the preferred method for controlling action 
is always a change in the design. When the design change is not viable solution, protective 
measures, for example automatic cut-offs or alarms, can be added. The last risk control 
measure, information for safety, is limited in effectiveness and should therefore be 
generally avoided [Schmuland, 2005]. The additional requirement from IEC 62304 states 
that if the risk control measure is implemented as a part of the function of the software, 
it must be included in the software requirements [IEC, 2006]. 
Information for safety promotes risk awareness. It explains the overall residual risk 
in a manner which allows users to minimize exposure to the residual risks. The 
information for safety might be communicated in different ways, for example with 
warning label, user interface or operation manual [ISO, 2012]. The applicable 
communication media should be analyzed and decided as necessary. Furthermore, the 
level of detail, the wording and understandability and the immediate recipients should be 
considered.  
ISO 14971 offers a shortcut for risk control to the situations where risk reduction is 
not practicable. However, the risk/benefit argument should be cautiously used only in 
exceptional circumstances as the remaining risk seriously compromises the safety and 
thus suitability of the product. ISO 14971 defines that risk/benefit argument can be used 
only in situations where the product brings substantial medical benefit [ISO, 2012]. In 
practice, medical benefit denotes the likelihood and extent of improvement of health 
expected from use of the device. Usually this kind of medical device is a breakthrough 
product for which there is no alternative treatment available [Schmuland, 2005]. The 
decision to use risk/benefit argument is a matter of judgment by experienced person and 
requires knowledge about technical, clinical, regulatory, economic, sociological and 
political context [ISO, 2012]. Therefore, it is recommended that the decision is essentially 
accepted by the top management representative as it has such considerable effect to the 
overall quality of the product.  
There exist several appropriate ways to control the risks related to architectural 
design. For example, critical components can be isolated and thus specific hazard causes 
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can be prevented. Effective method to control inputs from external interfaces is to use 
whitelisting that prevents all unknown commands and data formats [Pinto & Stuttard, 
2011]. Suitable redundancy strategies should be used in the complex systems including 
critical interface dependencies.  
The risks of detailed software design can be controlled with defensive design and 
coding practices. It is important to ensure that no unspecified functionality will be 
implemented [IEC, 2009]. In certain safety-critical situations, it might be necessary to 
clearly separate the safety-related and non-safety-related code. However, this practice has 
a high maintenance cost and thus cannot be commonly recommended.  
6.6. Proposed development model 
IEC/TR 80002-1 [2009] is a technical report that provides practical guidance for the 
application of the ISO 14971 to medical device software. The document presents a 
mapping grid between software development lifecycle and risk management in Annex D. 
While the grid does not include agile concepts, it is not intended to represent a strict 
sequential waterfall lifecycle and thus it is extremely useful as a reference when planning 
ISO 14971 implementation. The suitable agile concepts can be added as practicable. The 
proposed development model discussed in this section is influenced by the guidance 
provided in IEC/TR 80002-1.  
 
Figure 10. Reference development model: high level of abstraction. 
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Figure 10 presents the proposed development model at a high abstraction level. The 
regulatory requirements are addressed within different process phases as applicable. The 
requirement management activities are not addressed with more details in the scope of 
this thesis as they are not part of ISO 14971. Nevertheless, they are present in Figure 10 
to secure the compliance with other related standards.   
6.6.1. The Product vision statement as a documentation of intended use 
The product vision statement is a relatively short, single page document that describes 
the essence of the product to be developed. The vision describes why the product should 
be manufactured and the problems or the opportunities it addresses [Shore & Warden, 
2007]. The emphasis should be on value – how the software will benefit the customer 
and why it is valuable. Success criteria of the project should also be defined. Schwaber 
[2004] suggests that the major features and functions of the software could be listed in 
the vision statement. However, the implementation details should be scoped out as they 
should be defined by the development team later in the project.  
ISO 14970 states that intended use of the medical device with characteristics related 
to safety must be documented. Reasonable agile process artifact for this documentation 
is the vision statement. In addition to intended use, the reasonably foreseeable misuse 
should be considered. In the context of software product, the misuse can happen, for 
example, as a result of configuration error.  
As a recommended addition to previously mentioned vison statement sections, the 
business strategy benefits of the manufacturing organization should be addressed to 
ensure the profitability of the development project.  
6.6.2. Product backlog 
Backlog mechanism is very useful method to conduct agile requirements management 
activity. From regulatory perspective, requirements documentation must cover all areas 
that are required by regulations [AAMI TIR45, 2012]. Applicable documentation 
techniques are, for example, stories and use cases, textual descriptions, user interface 
mockups, UML-diagrams and control flows. With respect to agile perspective, the 
requirements documentation should be useful for the development team by providing 
actual value. 
Product backlog is a prioritized list of all the features that might be needed in the 
product. It is an evolving artifact that obtains new items as the collective knowledge 
increases. A typical form of the valuable backlog item is epic, use case or story, other 
forms are used for non-functional requirements and infrastructure items. It is arguable if 
these technical issues should be placed to the backlog as independent items or if they 
should be presented only through a certain customer-meaningful requirement that 
actually has customer value. Non-functional requirements can be particularly expensive 
since they typically affect the design and testing of large number of other requirement 
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implementations. Therefore, the need and scope of certain non-functional requirement 
should be considered carefully before being accepted. One reasonable place for non-
functional requirement is acceptance criteria (and definition of done) of the related use 
case. Regardless of the selected practice, the detected software defects yet not fixed and 
exploration activities should be placed to backlog as stand-alone items.   
The activity of prioritization is important since the items on the top of the list are the 
most valuable features and thus should be implemented next. Furthermore, the backlog 
should be proactively administrated, managed and organized in order to stay in consistent 
state [Rubin, 2013]. The product backlog management is ongoing process lasting the 
whole lifecycle of the project.  
The importance of ability to respond to change is emphasized in agile perspective, 
thus the change management process must be solid. The change request items can be 
placed to product backlog and prioritized accordingly. As with new features in backlog, 
the same development process can be used to implement the change requests. This 
practice ensures that change management process is controlled and change requests are 
well tested and verified.  
6.6.3. Release planning and verification 
Release is a coherent set of features which add the largest possible amount of value to the 
product. As the release activities do carry a fixed cost, it is important to understand all 
related cost components. When this information is visible, it is possible to seek ways to 
reduce the total cost. All the release activities that can be carried out at the end of each 
iteration should be placed accordingly. The routine to release often shortens the feedback 
cycle and reduces distress, risks and the amount of incorrect assumptions [Kniberg, 
2011].  
While the agile perspective has a vision that the product could be released after every 
increment, this approach might not be practical with every project in medical device 
domain. Even when the release activities are cut to the minimum, the inevitable cost can 
be too high to be paid after every iteration. The practical solution to this is to strive for 
working software after every iteration but to plan a broad level releases and to allocate 
needed time for release activities and verification [AAMI TIR45, 2012]. Thus, the end 
result of the iteration is near-shippable product that is missing only regulatory approval. 
The final requirements of the release might not be ready at release planning phase. 
Instead, requirements evolve during every iteration between the release cycle. 
Nevertheless, the release planning is natural development phase to perform risk analysis 
concerning the software requirements. The challenge of evolving requirements can be 
addressed by keeping the risk analysis of software requirements open until the 
requirements are finalized at the end of the release cycle 
In software requirement risk analysis, the known and foreseeable hazards are 
identified, including sequences or combination of events that could result in hazardous 
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situation. Moreover, the activities of installation, training, usage, upgrade and 
maintenance should be taken into account [IEC, 2009]. It is important to identify as many 
harm scenarios as possible. Finally, the identified risks should be estimated in order to 
enable the risk control measures at the later phases of the development, at the latest before 
the release cycle end.   
Even though it is impossible to identify every possible harm scenario, the most severe 
and probable should be feasible to discover with expert knowledge. One common method 
for risk identification is the brainstorming session by multidisciplinary group. According 
to Schmuland [2005], the design inputs should be analyzed regarding to safety – if the 
product is consistently built based on the design input specification, is it safe? Secondly, 
the design outputs should be validated to find possible safety compromises, for example 
operations that need certain sequence of events or decisions to be safe.  
Jeffries [2016] states that developers are often trained to design the architecture of 
the system at early state of the development. Upfront design is not ideal in an agile project 
since the requirement details are not known in advance. Therefore, the evolving agile 
architecture design should be done in several different development phases. Release 
planning phase should include a big-picture design that acts as a framework for more 
detailed design done in later phases of the development. The broad architectural vision is 
needed in order to be able to plan and estimate the release in a credible manner. The 
documentation of architecture must be complete at the time of release verification.  
Architectural design should be a subject of risk analysis. Critical data, components 
and classes of defects are identified with associated hazards. External interfaces can act 
as a source of unpredictable input and timing and therefore they must be carefully 
analyzed. Complex systems can include critical dependencies to external interfaces and 
thus provide potential hazards. Furthermore, the performance criteria and limitations 
must be considered. The software safety classification (as required in IEC 62304) has a 
notable effect on how rigorous the risk analysis process is.  
The agile practices that can be used to verify the architecture amongst others are 
continuous integration, automated testing and working software at the end of the iteration 
[AAMI TIR45, 2012]. These tools provide rapid feedback at regular intervals and 
therefore reduce the possibility of major problems.  
The final software version to be released must be verified with regulatory approval 
before releasing. In practice, this means that all risk management requirements must be 
fulfilled and the completeness of risk management is verified. All identified hazards are 
covered and all risks have been closed - no unhandled risks can remain when decision to 
release is made. Furthermore, regression testing of the implemented risk control measures 
is performed with complete traceability and coverage analysis to ensure that all risk 
control measures are implemented and tested [IEC, 2009]. The final requirements of the 
release must be gathered and documented.  
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Before releasing the product, overall residual risk must be evaluated to be acceptable. 
In overall residual risk evaluation, the residual risk is viewed from a broad perspective 
and it requires knowledge, experience and authority from the personnel performing the 
task. ISO 14971 does not define a specific method to be used in evaluation. Suitable 
methods are, for example, event tree analysis, review for conflicting requirements (of risk 
control measures), fault tree analysis, review of warnings, review of operating 
instructions, comparing risks (with other similar devices) and review by application 
experts. It is recommended to use application specialists that were not involved in the 
product development to get an unbiased view.  
Finally, the risk management report of the release must be compiled. These discussed 
risk management requirements and defined project adaptations should be formalized to 
definition of done convention of the release. As a result, the definition of done is a 
verification plan of the release. 
6.6.4. Iteration planning with iteration backlog 
Incremental development cycle is one of the most important practices of agile 
development. The development work of adapting and extending the software based on 
new requirements is done within short-duration iteration. Normally the iteration lasts 
between 1 to 4 weeks and the process is repeated multiple times during the single project. 
The short period improves team’s ability to respond to change, thus it is not generally 
recommended to use longer than one month cycles. Furthermore, strict timeboxing 
establishes an effective work in process (WIP) limit and thus reduces the amount of 
unfinished work. As a general approach and mindset, agile does not provide clear 
definition or strict rules for iteration execution. However, certain practices and principles 
from Scrum and XP are commonly used.  
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Figure 11. Reference iteration cycle. 
According to The Scrum Guide [2016], the iteration has three important principles: 
1) the general goal of the iteration cannot change during the iteration, 2) quality goals of 
the project cannot decrease during the iteration and 3) the scope of the iteration can be 
clarified and re-negotiated as knowledge is increased during the iteration. It is worth to 
notice that mentioned third principle is not shared between all agile and lean 
methodologies, although it is practical and realistic practice. In addition to these 
principles, iteration should produce largest possible amount of real value for customer or 
user. 
The product backlog is the most important input when planning the iteration. Only 
realistic amount of work should be selected to be placed in to the iteration backlog. The 
iteration planning is done just-in-time at the beginning of iteration when the best possible 
information is available to decide the most valuable new features [Rubin, 2012]. With 
this timing the ability to respond to change increases.  
 One emerging trend in agile field is to avoid estimating. Jeffries [2016] states: 
“Estimates are likely to be wrong and they focus attention on cost of things rather than 
value”. However, a little amount of estimation is inevitably needed in order to decide the 
appropriate workload for iteration. Beck & Fowler [2000] suggest a simple practice called 
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Yestardays Weather where planned workload is based on the amount of work done within 
last iteration. Nevertheless, this practice cannot work if iteration length is not fixed.  
Before placed in to the iteration backlog, the product backlog use case should have 
enough details that it can be prioritized and estimated, while the design details can still 
become more precise during the iteration. Kniberg [2011] suggest that special label 
“ready for development” could be used to indicate that the use case is ready to be added 
to the iteration. This concept has additional benefits when mapped to risk management 
process. For example, “ready for development” could indicate that risk analysis task 
related to that specific use case is started. This practice verifies that use case can not enter 
to iteration without being a subject of formal risk management analysis activity. 
Similarly, the importance of prioritization should be emphasized since it assures that the 
iteration produces the best possible value.    
Jeffries [2016] argues that agile project needs to have a high quality architectural 
design continually throughout the whole project. Therefore, architectural evaluation, 
design and refactoring activities must be carried out in every iteration – at the very least 
to ensure that new functionality implemented in the iteration is compatible with the 
existing high level architecture vision. During the iteration execution, the architecture 
vision guides the way how specific use cases are being implemented [AAMI TIR45, 
2012]. At the same time, the implementation details of a certain issue might influence the 
architecture. Consequently, the architecture evolves in every iteration as necessary since 
high quality of the architecture is solid foundation of an agile project. The architectural 
design must be documented as required by the regulatory framework, including the 
details how the detailed design activities are performed during the development process. 
When multiple teams are working in the same project, certain amount of coordination 
is needed to ensure that the items crossing the team boundaries are well synchronized. 
The best and most secure way to coordinate between the teams is to use automated tests 
[Jeffries, 2016]. 
The design in agile project should be simple enough just to produce the functionality 
that is needed in the current iteration artifact without any additional and speculative 
features that might or might not be needed in the future. This practice ensures that the 
team is always working with small and well-focused features that will bring largest 
possible amount of value for the current product. Furthermore, the team is able to break 
down the system to small pieces with robust and well-defined interfaces – it is important 
to notice that the interfaces are also design artifacts and must be documented accordingly. 
Verification of emerging design is done with automated tests and continuous integration. 
As the design evolves, additional potential causes for hazards might emerge and the 
existing ones can change, resulting the implemented risk control measures to expire. 
Therefore, the risk analysis must be reconsidered when planning the iteration. When 
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identifying the hazards, it is useful to consider data, coding and transmission errors with 
hardware failures.  
Overall, iteration and focus to working software are very practical and effective 
concepts to meet the regulatory requirement of integration strategy. In agile development, 
the integration and integration test activities are practically built in to daily development 
activities.  
6.6.5. Iteration execution  
The design and implementation of iteration backlog items must be verified during and 
after the iterations. The recommended agile practices to verify software units are 
automated unit, integration and acceptance tests in conjunction with peer review and 
continuous integration. The final requirements and the design of a use case are completed 
at the latest when the use case is done. The definition of done should be applied to ensure 
that all regulatory requirements are fulfilled, including the risk management activities. 
Different kind of deliverables can have different convention for definition of done and 
also item specific acceptance criteria can be used. Final requirements must be 
documented, approved and controlled. 
Active involvement of the customer during the iteration ensures that the requirements 
are correctly understood by the team. In practice, it is usual that the customer access can 
be limited, so special attention should be paid to reduce the risk of incorrect requirements 
and to ensure the effectiveness of requirements elaboration.   
The practice of daily builds is especially useful since it reduces the feedback cycle. 
Each change in the systems is verified with automated tests that are executed 
continuously in integration process. The intention of the tests is to verify the functionality 
and performance of the use cases. The executable specifications can be used to verify that 
business goals are delivered as defined. Depending on the complexity of the system, it is 
not always practicable to run all the integration tests locally several times during a day 
since running the tests can be time consuming activity. When this is the case, the 
continuous integration process should be placed to run in external server and to be 
triggered to start from version control system check-ins. This practice allows fastest 
possible integration feedback while not interfering the development of the next feature. 
Small size unit tests should also be used to verify the correctness of software units and 
functionality.  
The tests that fail at some point in time after the implementation had already being 
accepted should be a subject of risk analysis. The similar code implementations should 
be searched and evaluated if found. The implemented risk control measures should be 
verified in all possible range of conditions and platforms [IEC, 2009].  
Daily meeting is important inspect and adapt activity. The intention is to share 
common knowledge about the project and status of the current iteration and to plan 
immediate development activities. Besides focusing to the wider picture of the situation, 
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the synchronization helps team to avoid blocking and disrupting problems. Daily meeting 
can follow a practice familiar from Scrum where participants answer three questions: 
what did I accomplish yesterday, what do I plan to do today and are there any obstacles 
preventing me from making progress [Rubin, 2013]. However, it is also possible to use 
less formal approach if the objectives of the practice realize.  
In addition to daily meetings, the common knowledge is increased with collective 
plan and code reviews. These practices ensure that mistakes are reduced and thus improve 
the quality of the product. These reviews should be organized in a manner that satisfies 
the regulatory requirements and they should be documented accordingly. 
6.6.6. Iteration review with working software 
The iteration review is an inspect-and-adapt activity that focuses to the product itself by 
presenting the increment done during the iteration, thus the timing of iteration review 
should be near the end of the iteration cycle. Iteration review acts as a frequent checkpoint 
that offers a transparent view to state of the project. The focus is strictly limited to the 
product since the main measure of the agile project progress is working software 
[Medinilla, 2012]. The practice to demonstrate the working version of the software at the 
end of every iteration forces the development team to finish open issues in time and 
clearly makes visible which tasks are finished and which are not, as only completed work 
should be presented.  
The participants of the review should include all the interested parties of the project. 
In this way, the team is able to gather feedback about the product from the persons which 
are not usually available on a daily basis [Rubin, 2013]. The information flow in the 
review should be bidirectional – from development team to other participants as a demo 
of the software and back from stakeholders to the team as a feedback. The important 
aspect of the review is conversation and cooperation.  
At the beginning of the iteration, the items in iteration backlog can be incomplete and 
at the relatively high on abstraction level. The detail level of the item elaborates 
throughout the iteration and the requirements should be clear and precisely defined at the 
end. As a result, the item can be used as a formal requirement for the product. With this 
practice, the iteration backlog use cases can be validated and verified at iteration review 
as required by the regulatory framework and they can act as an input for final 
requirements documentation. As incorrectly implemented features can result a 
considerable safety problem, the importance of the verification cannot be overly 
emphasized.  Furthermore, the iteration review is natural development phase where all 
project deliverables are verified and product progression gets a formal approval.  
In order to close and verify the risk management activities of the iteration, the 
complete traceability and coverage analysis should be performed [IEC, 2009].  
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6.6.7. Retrospectives to seek continuous improvement 
The effectiveness of the adapted agile development method should be evaluated 
frequently in order to enable the continuous improvement of the model. This principle is 
defined in the Agile Manifesto. One common way to do the evaluation is to facilitate a 
team retrospective between the iterations. The relatively short time between 
retrospectives is recommended since it shortens the feedback cycle and the time in which 
the team is not operating in optimal level.  
Furthermore, the effectiveness of the regulatory requirement implementation must be 
validated regularly. The quality management system is monitored by audits: internal 
audits which are performed by organization's quality management representative and 
external audits which are performed by a regulatory-approval body. Naturally, it is 
reasonable to periodically evaluate the effectiveness of the quality management system 
also in team retrospectives to verify that the process is compliant with the regulatory 
expectations. 
The format of the retrospective can be formal or less formal. There exist several 
different retrospective techniques in agile methodologies to choose from, thus the 
practice can be tailored based on the unique needs of the team. The intention of the 
retrospective is to 1) inspect how the last iteration went (from the viewpoint of 
development process), 2) recognize successes and issues to improve and 3) create a plan 
for improvements [The Scrum Guide, 2016]. The overall goal is to improve the quality 
of the product and allow the team to become more effective and to get more pleasure 
from work.  
The default focus of retrospective is to consider the whole development process 
during the latest iteration. However, at certain times it can be useful to limit the scope to 
specific and important issue team is currently facing. Special attention should be paid to 
find out the root cause behind the improvement need. The outputs of the retrospective 
should be concrete improvement actions which the team is committed to perform during 
the next iteration. Furthermore, the improvement actions should follow the common agile 
practice of plan-do-check-act (PDCA). When the root cause has been found, the 
corrective action and concrete improvement goal is planned (plan). The plan is executed 
during the next iteration and data about the effects of the action is collected (do). After 
the iteration, the data is analyzed to see if the process has improved and goal is reached 
(check). The final phase is to change the process if the plan was successful or to reject 
the changes if the goal was not met (act). From the regulatory perspective, the check 
activity should be used to formally validate the results and the act activity defines the 
new routine practice.  
The quality management system requires the use of corrective and preventive action 
(CAPA) process as defined in ISO 13485. Therefore, all the development process 
anomalies should be documented and used as input to CAPA process.  
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6.7. Risk management activities following the release 
Medical device risk management process continues throughout the whole lifecycle of the 
device. After releasing the product, it is essential to monitor the field performance to 
ensure it correlates with expectations [Schmuland, 2005]. Furthermore, IEC 62304 
describes requirements for software maintenance and problem resolution processes and 
the risk management process should be integrated with them.  
When considering software product, there are several technical solutions to perform 
active monitoring. In addition, the system to collect customer feedback is needed as a 
part of problem resolution process. From the viewpoint of risk management, the customer 
feedback is analyzed to re-evaluate the overall residual risk of the product. If new or 
changed safety issues arise, the information provided by the feedback system must be fed 
back as an input to risk management process and the review must be conducted and 
documented [ISO, 2012]. 
6.8. Potential software related pitfalls of risk management process 
IEC/TR 80002-1 [2009, Annex C] provides a list of potential pitfalls related to medical 
device software risk management process. The list is relatively comprehensive and can 
be used as a checklist when evaluating the effectiveness of the risk management process.  
The common pitfall related to software development lifecycle is that software related 
risk management activities are performed only late in the development. This is a worrying 
sign of the possibility that software features have been added to the product without 
properly considering the related hazards and hazardous situations. Equally problematic 
situations can occur if certain relevant misuse scenarios or use environments are not 
recognized.   
As discussed earlier in Section 6.4, software product related risk probability 
estimation can be difficult. As a result, unrealistic low probability estimates can be 
applied, resulting unrealistic risk ratings and correspondingly inappropriate risk control 
measures. It should be noticed that as testing can never be exhaustive, it cannot eliminate 
the risk completely and reduce the related risk probability to zero. Furthermore, clinical 
knowledge is needed in order to be able to adequately estimate the severity of the risk.  
The risk control measures implemented as software items can make the design more 
complex. It is obvious that the increased software complexity also increases the 
probability of software defects. Furthermore, all the risk control measures should be 
validated under a wide range of abnormal and stress conditions. A common characteristic 
of software is that certain defects are particularly difficult to produce in test environment. 
However, these risk control measures must also be verified as required by ISO 14971.  
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7. Conclusions 
The aim of this thesis was to research similarities and differences between the ISO 14971 
risk management process and agile principles. Therefore, the International Standard ISO 
14971 was carefully analyzed and the requirements were gathered. Furthermore, the agile 
philosophy was examined through the value statements and principles defined originally 
in the Agile Manifesto.  
Besides studying the theory behind these two concepts, the aim was to provide 
guidance and produce practical ideas for implementation of the risk management process 
that meets the regulatory requirements and, at the same time, follows agile values and 
principles. Accordingly, the example development process model was designed to be 
used as a reference implementation. However, the actual process implementation must 
always be designed based on the unique set of conditions that apply to the organization 
and circumstances.  
By following the given guidance and instructions the medical device software 
manufacturers should be able to create the applicable risk management process and to 
claim conformity to ISO 19471. While it is possible to be adaptive with agile practices, 
the regulatory requirements must be followed in detail. For the organizations, it is 
essential to know and truly understand all the relevant regulatory requirements to ensure 
that the full conformity assessment can be made.  
7.1. Agile and risk management process of ISO 14971 
The intention of agile philosophy is not to completely ban processes and project 
documentation. Instead, the importance of personal interaction and communication is 
emphasised for knowledge sharing activity.  Therefore, the agile processes should be 
designed to support direct communication between the participants and, from the 
regulatory viewpoint, there are no barriers for a communication-centric approach.  
From agile perspective, the project documentation does not produce direct value to 
the end user and should be therefore limited to the minimum. It is not difficult to see that 
regulatory process requirements for documentation can be inefficient to a certain degree. 
Nevertheless, they do bring business value to the product since only few patients or 
healthcare professionals would want to use a medical device that is manufactured 
unfettered by the regulatory framework.  
The ability to respond to change is one of the four value statements of the Agile 
Manifesto. This value is clearly contradicting with the regulatory perspective, where 
change is seen as a sign of process and design flaw. This raises a serious question whether 
agile practices are too undisciplined to be used in the regulated environment. However, 
this research indicates that there are no actual barriers to use agile planning practices in 
medical device software development. While the regulatory requirements do dictate 
certain additional subjects to be addressed in planning documentations, these 
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requirements can be fulfilled by extending related agile tools and techniques. The 
recommended way to address this issue is to focus on high-level regulatory development 
process documentation and to use suitable agile practices to generate plans for more 
detailed tasks. The overall software development plan should cover all regulatory 
requirements.  
The primary goal of the regulatory framework is to ensure the safety of medical 
devices. Similarly, also the agile approach has a client focus - the aim is to maximize the 
value from the client’s perspective. These objectives are well aligned as the safety is one 
of the most valuable features of medical devices. Using agile practices also brings certain 
risk management related advantages: collaboration and communication increase the 
overall quality and allow more efficient risk detection, continuous integration produces 
feedback and visibility to the effectiveness of risk management, and finally, continuous 
feedback and validation also increase safety and usability related knowledge. 
7.2. Usefulness of the research 
Agile practices do not directly address subjects related to risk planning or risk assessment. 
The previous research in the field has focused either on agile concepts or on the risk 
management process of ISO 14971. However, there is a lack of research on the 
integration. This research provides ideas and guidelines for the integration and proves 
that agile practices integrate well with risk management activities. Therefore, this thesis 
clearly makes a contribution to the field.  
There is no end state in agile implementation process. In agile approach, the 
continuous process improvement is cherished in order to become more efficient with the 
development activities. Similarly, the quality management system and the risk 
management process are always under transition to become more effective. 
7.3. Limitations and further research 
The scope of this thesis is limited to the ISO 14971 risk management process. As a result, 
not all the requirements of the regulatory framework and the standards within have been 
taken into account in this research. For example, IEC 62304 includes a great number of 
requirements for design documentation and configuration management that have been 
scoped out. However, the risk management implementations based on the ideas of this 
research should be compliant with other related regulatory requirement standards as there 
are no known or recognized conflicts; requirements from other standards can be added 
where applicable. Therefore, the requirements of IEC 62304 and IEC 62366-1 would be 
relevant and interesting subjects to be addressed in further research. 
7.4. Recommendations 
When designing the process implementation, it is essential to thoroughly understand the 
goals and principles of the regulatory framework. The formal language and unique terms 
used in the standards can be difficult to understand at the beginning, although the 
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understanding of the complete context deepens with more experience with the concepts. 
The baseline is set with the accurate safety classification of the device and correctly 
selected set of applicable standards. 
It is important to notice that the regulatory framework is constantly evolving and 
manufacturers are responsible for keeping their processes aligned with the most recent 
requirements. This is considerable managemental issue in organizations; thus, 
participating in the work of related associations in the field is strongly recommended. For 
example, the Finnish Health Technology Association (FiHTA) provides the most recent 
news and information concerning international medical device regulations.  
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